var title_f26_13_26832="Contents: Cerebrovascular disease";
var content_f26_13_26832=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cerebrovascular disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cerebrovascular disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Carotid artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/66\">",
"           Carotid artery stenting and its complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6617\">",
"           Coronary artery bypass grafting in patients with cerebrovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31033\">",
"           Evaluation of carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/33/16922\">",
"           Management of asymptomatic carotid atherosclerotic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21530\">",
"           Management of symptomatic carotid atherosclerotic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/24/9608\">",
"           Pathophysiology of symptoms from carotid atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34361\">",
"           Screening for asymptomatic carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30682\">",
"           Secondary prevention of stroke: Risk factor reduction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebral embolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39689\">",
"           Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10809\">",
"           Embolism from aortic plaque: Thromboembolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31994\">",
"           Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/32/3593\">",
"           Patent foramen ovale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14328\">",
"           Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Classification",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19112\">",
"           Intracranial epidural hematoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2010\">",
"           Intracranial large artery atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6009\">",
"           Intraventricular hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39273\">",
"           Posterior circulation cerebrovascular syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30230\">",
"           Spinal cord infarction: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23333\">",
"           Spinal cord infarction: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40631\">",
"           Spinal cord infarction: Vascular anatomy and etiologies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/406\">",
"           Subarachnoid hemorrhage grading scales",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6936\">",
"           Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43767\">",
"           Subdural hematoma in adults: Prognosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24458\">",
"           Cerebrovascular disorders complicating pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/63/34807\">",
"           Locked-in syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/12/17610\">",
"           Medical complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25271\">",
"           Neurogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/47/3834\">",
"           Neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2168\">",
"           Prevention of neurologic complications of cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10087\">",
"           Stroke-related pulmonary complications and abnormal respiratory patterns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation and acute management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31688\">",
"           Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/11/10426\">",
"           Initial evaluation and management of transient ischemic attack and minor stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17290\">",
"           Neuroimaging of acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intracerebral hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/6/32872\">",
"           Brain arteriovenous malformations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37001\">",
"           Cerebral amyloid angiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/55/6009\">",
"           Intraventricular hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10298\">",
"           Management of warfarin-associated intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ischemic stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39689\">",
"           Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11530\">",
"           Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40105\">",
"           Cryptogenic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/35/569\">",
"           Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18773\">",
"           Definition of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36439\">",
"           Differential diagnosis of transient ischemic attack and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9208\">",
"           Etiology and classification of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40678\">",
"           Etiology and clinical manifestations of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2010\">",
"           Intracranial large artery atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/26/6570\">",
"           Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/59/4026\">",
"           Lacunar infarcts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/249\">",
"           Pathophysiology of ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39383\">",
"           Stroke in patients with atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9482\">",
"           Treatment and prognosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14328\">",
"           Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/35/33337\">",
"           Use and utility of stroke scales and grading systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mechanisms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40105\">",
"           Cryptogenic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7594\">",
"           Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32953\">",
"           Headache, migraine, and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7751\">",
"           Moyamoya disease: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/249\">",
"           Pathophysiology of ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10730\">",
"           Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/39/36471\">",
"           Subclavian steal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9482\">",
"           Treatment and prognosis of cerebral venous thrombosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/35/2618\">",
"           Antiplatelet therapy for secondary prevention of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5576\">",
"           Overview of primary prevention of coronary heart disease and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/60/40906\">",
"           Secondary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30682\">",
"           Secondary prevention of stroke: Risk factor reduction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Role of anticoagulation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/57/8089\">",
"           Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33348\">",
"           Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30327\">",
"           Anticoagulant and antiplatelet therapy in patients with brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27849\">",
"           Risk of intracerebral hemorrhage in patients treated with warfarin",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Subarachnoid hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44806\">",
"           Late recurrence of subarachnoid hemorrhage and intracranial aneurysms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10298\">",
"           Management of warfarin-associated intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/50/38696\">",
"           Nonaneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/18/6441\">",
"           Perimesencephalic nonaneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/43/3767\">",
"           Screening for intracranial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21960\">",
"           Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/406\">",
"           Subarachnoid hemorrhage grading scales",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25225\">",
"           Unruptured intracranial aneurysms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transient ischemic attack",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18773\">",
"           Definition of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40678\">",
"           Etiology and clinical manifestations of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/11/10426\">",
"           Initial evaluation and management of transient ischemic attack and minor stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13624\">",
"           Clinical features and diagnosis of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9641\">",
"           Clinical manifestations and diagnosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34314\">",
"           Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25386\">",
"           Primary angiitis of the central nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28119\">",
"           Treatment and prognosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FF1685AAC6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_13_26832=[""].join("\n");
var outline_f26_13_26832=null;
var title_f26_13_26833="Patient information: Uveitis (The Basics)";
var content_f26_13_26833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82908\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25953\">",
"         Uveitis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/3/20529\">",
"         Patient information: Chorioretinitis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Uveitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/uveitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26342142\">",
"      <span class=\"h1\">",
"       What is uveitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Uveitis is a rare condition that affects the middle part of the eye, called the &ldquo;uvea&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef82775 \" href=\"UTD.htm?25/22/25953\">",
"       figure 1",
"      </a>",
"      ). Uveitis that affects the front part of the eye is called &ldquo;anterior uveitis&rdquo; or &ldquo;iritis.&rdquo; The symptoms are caused by inflammation and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A red eye",
"       </li>",
"       <li>",
"        Eye pain",
"       </li>",
"       <li>",
"        Being very uncomfortable looking at bright lights",
"       </li>",
"       <li>",
"        A small pupil &ndash; The pupil is the dark, round area at the center of the eye.",
"       </li>",
"       <li>",
"        Blurred vision",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Uveitis that affects the back of the eye is called &ldquo;posterior uveitis.&rdquo; The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blurred vision",
"       </li>",
"       <li>",
"        Floaters &ndash; These are tiny, dark spots that move across your line of sight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But having these symptoms does not necessarily mean you have uveitis. &nbsp;Different eye conditions can cause some or all of these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26342157\">",
"      <span class=\"h1\">",
"       What causes uveitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many different things can cause uveitis, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Infections &ndash; These can be caused by viruses or bacteria.",
"       </li>",
"       <li>",
"        Autoimmune diseases &ndash; These are diseases in which the body&rsquo;s infection-fighting system attacks healthy tissue instead of infections. Autoimmune diseases can cause inflammation in the eye and other parts of the body.",
"       </li>",
"       <li>",
"        Eye injuries",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26342172\">",
"      <span class=\"h1\">",
"       Should I see a doctor or a nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See a doctor if you have any symptoms of uveitis. Uveitis can cause vision loss if it is not treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26342189\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your medical history. You will need an eye exam. Other tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A complete physical exam",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26342204\">",
"      <span class=\"h1\">",
"       How is uveitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the type and cause of the uveitis. Treatments can include eye drops, pills, or injections (shots) directly into the eye. Several of these treatments are steroid medicines that help reduce inflammation. These medicines are different than the steroids that athletes take to build up muscle.",
"     </p>",
"     <p>",
"      Your doctor might prescribe some or all of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eye drops that contain steroids",
"       </li>",
"       <li>",
"        Eye drops to ease pain",
"       </li>",
"       <li>",
"        Steroid pills",
"       </li>",
"       <li>",
"        Steroid injections into the eye (for posterior uveitis)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Other medicines to treat the condition that is causing your uveitis",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14193439\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=see_link\">",
"       Patient information: Chorioretinitis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/13/26833?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82908 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26833=[""].join("\n");
var outline_f26_13_26833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26342142\">",
"      What is uveitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26342157\">",
"      What causes uveitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26342172\">",
"      Should I see a doctor or a nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26342189\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26342204\">",
"      How is uveitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14193439\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25953\">",
"      Uveitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20529?source=related_link\">",
"      Patient information: Chorioretinitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26834="Beano (alpha-galactosidase): Drug information";
var content_f26_13_26834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beano (alpha-galactosidase): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3281365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      beano&reg; Meltaways [OTC];",
"     </li>",
"     <li>",
"      beano&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3281369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3281389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Flatulence and bloating:",
"     </b>",
"     Oral: Adjust dose according to the number of problem foods per meal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable (beano&reg;): Usual dose: 2-3 tablets/meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating (beano&reg; Meltaways): One tablet per meal",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3281388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Flatulence and bloating: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3281390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3281395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     beano&reg;: 150 Galactosidase units [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     beano&reg; Meltaways: 300 Galactosidase units [strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3281367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3281392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be administered just before or with first bite of food to be effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chewable tablet (beano&reg;): Swallow, chew, or crumble on food. Take before or with initial bite of food; do not cook.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally-disintegrating tablets (beano&reg; Meltaways): Take before meals; place on tongue and allow to dissolve.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3281370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of flatulence and bloating attributed to a variety of grains, cereals, nuts, and vegetables",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       beano&reg; may be confused with B&amp;O (belladonna and opium)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3281371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3281372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Patients with diabetes mellitus should consult a healthcare provider prior to use; can produce 2-6 g of carbohydrates for every 100 g of food treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Galactosemic patients: Patients who are galactosemic should consult their healthcare provider prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Patients who are pregnant or breast-feeding should consult a healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Approved use: Currently, there are no FDA-approved disease-prevention or therapeutic indications for this product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat exposure: Heat can inactivate; do not cook.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3281391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken just before or with initial bite of food to be effective. Although made from safe, food-grade mold, there is no evidence that individuals with an allergy to penicillin or molds would have an allergy to beano&reg;. Galactosemics should consult their healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3281384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Natural food enzyme that breaks down complex sugars in gassy foods, making them more digestible and less gassy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DiStefano M, Miceli E, Gotti S, et al, &ldquo;The Effect of Oral Alpha-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms,&rdquo;",
"      <i>",
"       Dig Dis Sci",
"      </i>",
"      , 2007, 52(1):78-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/13/26834/abstract-text/17151807/pubmed\" id=\"17151807\" target=\"_blank\">",
"        17151807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Alpha-Galactosidase to Prevent Gas,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(893):29-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/13/26834/abstract-text/8383798/pubmed\" id=\"8383798\" target=\"_blank\">",
"        8383798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8828 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26834=[""].join("\n");
var outline_f26_13_26834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281365\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281369\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281389\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281388\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281390\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671400\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671401\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281395\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281367\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281392\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914572\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281371\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281372\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281391\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281384\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8828|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26835="Lumbar puncture PI";
var content_f26_13_26835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Lumbar puncture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a lumbar puncture, the doctor inserts a needle between 2 of the bones that make up the spine. Then he or she uses the needle to collect a small sample of fluid from around the spinal cord. The needle goes in below the point where the spinal cord is a solid cord, so it is unlikely to get injured by the needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26835=[""].join("\n");
var outline_f26_13_26835=null;
var title_f26_13_26836="Foil splint for fingertip avulsion";
var content_f26_13_26836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Foil splint for fingertip avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sterile foil from a suture packet is cut to fit in the proximal fold and sutured in place through the lateral skin folds using absorbable 4-0 suture or skin glue (eg, cyanoacrylate glue). This approach helps preserve the proximal fold as the new nail grows in.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesty of Richard A Saladino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26836=[""].join("\n");
var outline_f26_13_26836=null;
var title_f26_13_26837="Intraluminal cal meconium";
var content_f26_13_26837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraluminal calcified meconium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraluminal calcified meconium present in an autolyzed 16 week fetus. This finding is seen often in Trisomy 21 but can also be seen in cases of intestinal atresias or in congenital cystic fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26837=[""].join("\n");
var outline_f26_13_26837=null;
var title_f26_13_26838="Massive hemoptysis: Causes";
var content_f26_13_26838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Massive hemoptysis: Causes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26838/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26838/contributors\">",
"     David H Ingbar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26838/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26838/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/13/26838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11003158\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with massive hemoptysis, the initial steps are to correctly position the patient, establish a patent airway, insure adequate gas exchange and cardiovascular function, and control the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/1\">",
"     1",
"    </a>",
"    ]. The source of bleeding may be identified either during efforts to control the bleeding or during a careful evaluation after the patient has been stabilized. The cause of the bleeding determines the appropriate definitive treatment.",
"   </p>",
"   <p>",
"    Potential causes of massive hemoptysis are described here. Other aspects of massive hemoptysis (ie, definition, initial management, diagnostic evaluation, and definitive treatment) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29558?source=see_link\">",
"     \"Overview of massive hemoptysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003737\">",
"    <span class=\"h1\">",
"     CAUSES OF MASSIVE HEMOPTYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before assuming that the source of bleeding is the lower respiratory tract, the possibility that the blood may be coming from a non-pulmonary source, such as the upper airway or the gastrointestinal tract, should be considered. This distinction can be difficult and may require an otolaryngological or gastrointestinal evaluation. Characteristics of the expectorated material that suggest that a gastrointestinal source is unlikely include an alkaline pH, foaminess,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of pus.",
"   </p>",
"   <p>",
"    There are numerous causes of bleeding from the lower respiratory tract. Many are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62661 \" href=\"UTD.htm?36/43/37565\">",
"     table 1",
"    </a>",
"    ). Three etiologies accounted for 90 percent of the cases of massive hemoptysis through the 1960s: tuberculosis, bronchiectasis, and lung abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"     2",
"    </a>",
"    ]. Each of these causes has since decreased in frequency, although other etiologies have increased (",
"    <a class=\"graphic graphic_table graphicRef66122 \" href=\"UTD.htm?14/29/14812\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. There are no more recent large series examining the prevalence of the causes of massive hemoptysis in general hospital settings. In this section, we describe the most common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    important causes of massive hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4654462\">",
"    <span class=\"h2\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bronchial circulation supplies blood flow to the bronchial wall. In bronchiectasis, chronic airway inflammation causes hypertrophy and tortuosity of the bronchial arteries that accompany the regional bronchial trees, as well as expansion of the submucosal and peribronchial plexus of blood vessels. Rupture of either the tortuous vessels or the capillary plexus results in rapid bleeding because these blood vessels are subjected to systemic blood pressure.",
"   </p>",
"   <p>",
"    Bronchiectasis may result from prior bacterial or viral infection, cystic fibrosis, TB, host immune defects, or impairment of the mucociliary clearance apparatus (eg, ciliary dyskinesia associated with Kartagener's syndrome or Young's syndrome). The increasing survival of patients with cystic fibrosis into adulthood has made cystic fibrosis an increasingly common cause of massive hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/8\">",
"     8",
"    </a>",
"    ]. Bronchiectasis is increasingly recognized in patients with alpha-1 antitrypsin deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\", section on 'Etiologies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003744\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive hemoptysis can be a consequence of either active or prior tuberculosis (TB).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active TB &ndash; Massive hemoptysis due to active TB can occur in the setting of cavitary or noncavitary disease. Most patients have sputum smears that stain positive for acid-fast bacilli. The cause of the bleeding is usually bronchiolar ulceration with necrosis of adjacent blood vessels and distal alveoli [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"       2",
"      </a>",
"      ]. This type of bleeding is from the bronchial arterial circulation. Less often, active TB may cause sudden rupture of a Rasmussen's aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/9\">",
"       9",
"      </a>",
"      ]. This is an aneurysm of the pulmonary artery that slowly expands because of inflammatory erosion of the external vessel wall until it bursts. There is some uncertainty about whether these aneurysms can also arise from bronchial arteries.",
"     </li>",
"     <li>",
"      Prior TB &ndash; There are numerous causes of hemoptysis due to prior TB. These include the erosion of a healed calcified lymph node (ie, broncholith) through a bronchial artery and into an airway, bronchiectasis due to structural lung damage from prior TB, and a mycetoma in a lung cavity from prior TB. Scar carcinomas in areas of prior TB can cause hemoptysis, although this is rare. Late rupture of a Rasmussen's aneurysm has been reported in patients with prior TB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ongoing importance of TB as a cause of massive hemoptysis in some parts of the world was illustrated by a case series of 120 South African patients with massive hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/5\">",
"     5",
"    </a>",
"    ]. Active TB was the cause of 73 percent of the cases of massive hemoptysis. Among the patients with TB-related massive hemoptysis, most had either bronchiectasis or cavitation, although approximately one-third had non-cavitary active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003758\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infections in the lung have increased in frequency, especially among patients with preexisting cavitary disease and immunocompromised patients (eg, bone marrow transplantation). Types of pulmonary fungal infections include mycetomas (such as aspergillomas), invasive parenchymal fungal infections (eg, chronic necrotizing pulmonary aspergillosis), and dimorphic fungal infection (eg, histoplasmosis, blastomycosis):",
"   </p>",
"   <p>",
"    An aspergilloma is a fungus ball composed of Aspergillus hyphae, fibrin, mucus, and cellular debris that is found within a pulmonary cavity. Aspergillomas arise in preexisting pulmonary cavities that have become colonized with Aspergillus species. They are the fungal infection that is most commonly associated with hemoptysis. Among patients with an aspergilloma, hemoptysis occurs in 50 to 90 percent of patients and may be massive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"     2",
"    </a>",
"    ]. The exact cause of bleeding due to an aspergilloma is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive parenchymal fungal infections may also cause massive hemoptysis, particularly infections caused by the angioinvasive fungi Aspergillus and Mucor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"     2",
"    </a>",
"    ]. The fungi destroy parenchymal and vascular structures, thereby inducing hemorrhage. When the invasive parenchymal fungal infection occurs after bone marrow transplantation, bleeding may be more likely at the time when bone marrow production of neutrophils is returning, since local inflammation may increase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute dimorphic fungal infections of the lung rarely cause hemoptysis and, when they do, it is likely a consequence of mucosal erosion. Prior histoplasmosis has been reported as a potential cause of hemoptysis, either due to the invasion of a calcified lymph node through an airway and vasculature or the effects of fibrosing mediastinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003765\">",
"    <span class=\"h2\">",
"     Other lung infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other lung infections (particularly lung abscess) can also cause massive hemoptysis. Regardless of the type of lung infection, bleeding may occur acutely from necrosis of lung tissue or rupture of hypertrophied bronchial arteries due to chronic inflammation. Bacterial pneumonia occasionally causes massive hemoptysis, especially in individuals with thrombocytopenia or coagulopathy. In developing countries, parasitic infections are very common etiologies of hemoptysis, particularly paragonimiasis in Southeast Asia. Severe leptospirosis may be complicated by massive alveolar bleeding and hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4654544\">",
"    <span class=\"h2\">",
"     Bronchogenic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchogenic carcinoma is a common cause of hemoptysis, but an infrequent cause of massive hemoptysis. Nonmassive hemoptysis exists in 7 to 10 percent of patients with lung cancer at the time of presentation and occurs in approximately 20 percent of patients at some time during their course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, massive terminal hemoptysis occurs in only 3 percent of patients with lung cancer, according to a series of 877 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/12\">",
"     12",
"    </a>",
"    ]. Among the patients who had massive hemoptysis, 80 percent had small, sentinel bleeding episodes during the prior weeks. Patients with massive hemoptysis typically had large, centrally located tumors, especially squamous cell carcinoma. Hemoptysis is also common in patients with bronchial carcinoid tumors, but the amount of bleeding is quite variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11004547\">",
"    <span class=\"h2\">",
"     Bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether bronchitis alone is sufficient to cause massive hemoptysis. Many clinicians believe that coagulopathy or other contributing factors must be present for massive hemoptysis to occur in the setting of bronchitis alone. Case series have reported bronchitis as the cause of massive hemoptysis in 5 to 37 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/3,4,6,13\">",
"     3,4,6,13",
"    </a>",
"    ]. However, since computed tomography of the chest was rarely performed in these older series, it is possible that many of the patients actually had underlying bronchiectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003786\">",
"    <span class=\"h2\">",
"     Immunologic lung diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse parenchymal lung diseases with an immunologic basis can cause massive hemoptysis, probably due to pulmonary capillaritis. Examples include Goodpasture's syndrome, granulomatosis with polyangiitis (formerly called Wegener's granulomatosis), systemic lupus erythematosus (SLE), idiopathic pulmonary hemosiderosis, and microscopic polyangiitis.",
"   </p>",
"   <p>",
"    Patients with these diseases may also develop diffuse alveolar hemorrhage. The clinical features and causes of diffuse alveolar hemorrhage are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef72772 graphicRef51544 \" href=\"UTD.htm?39/61/40925\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In diffuse alveolar hemorrhage, the degree of hemoptysis may be relatively small compared to the amount of parenchymal bleeding. The reason for this observation is that the alveolar location of the bleeding may not stimulate the cough reflex to the same extent as bleeding in the airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4653942\">",
"    <span class=\"h2\">",
"     Chemotherapy and bone marrow transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are undergoing chemotherapy for leukemia or who have received a bone marrow transplant may have sudden, massive pulmonary hemorrhage that is frequently fatal. The etiology of this idiopathic pneumonia syndrome after bone marrow transplantation is uncertain, but postmortem pathology suggests that it is due to diffuse lung injury, presumably from a combination of drugs, radiation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia. There may also be contributions from underlying fungal or viral infection. Alternatively, patients may develop diffuse alveolar hemorrhage and respiratory failure, which can manifest with little or no hemoptysis. Idiopathic pneumonia syndrome and diffuse alveolar hemorrhage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003793\">",
"    <span class=\"h2\">",
"     Cardiac and vascular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac and vascular etiologies are potential, albeit infrequent, causes of massive hemoptysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary arteriovenous malformations can bleed, regardless of whether there is one or multiple and regardless of whether they are due to hereditary hemorrhagic telangiectasia (HHT, also called Osler-Weber-Rendu syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. More than 8 percent of patients with pulmonary arteriovenous malformations due to HHT will have an episode of massive hemoptysis, according to a series of 143 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26838/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link&amp;anchor=H6#H6\">",
"       \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\", section on 'Symptoms and signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitral stenosis increases resistance in the pulmonary veins, accompanied by reversal of blood flow from the pulmonary capillaries into the bronchial veins. The resulting submucosal bronchial varices may rupture, causing \"cardiac apoplexy.\" This is prone to manifest at times of either increased pulmonary blood flow (exercise, pregnancy) or increased blood volume (pregnancy). Although now rare in the United States, it is worthwhile obtaining echocardiography to exclude this cause of hemoptysis. Cardiopulmonary bypass can markedly reduce such bleeding and should be considered if the bleeding is life-threatening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathophysiology, clinical features, and evaluation of mitral stenosis\", section on 'Hemoptysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary emboli usually cause scant hemoptysis due to a small peripheral pulmonary infarction. However, the hemoptysis may become massive after the initiation of anticoagulant therapy or the use of a thrombolytic agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right heart catheterization (also called pulmonary artery catheterization or Swan Ganz catheterization) can result in iatrogenic pulmonary artery perforation and the sudden onset of massive hemoptysis. Predispositions include pulmonary hypertension and having the catheter tip too distal in the pulmonary circulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link&amp;anchor=H8#H8\">",
"       \"Pulmonary artery catheterization: Indications and complications\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septic pulmonary emboli from right-sided infective endocarditis occasionally may result in massive hemoptysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of pulmonary disease in injection drug users\", section on 'Septic emboli'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart disease or severe pulmonary hypertension can cause significant hemoptysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=see_link&amp;anchor=H7#H7\">",
"       \"Hemoptysis in children\", section on 'Pulmonary vascular disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic aneurysm can present with either submassive or massive hemoptysis. The mechanism for hemoptysis is not well defined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features and diagnosis of thoracic aortic aneurysm\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11004209\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before assuming that the source of bleeding is the lower respiratory tract, the possibility that the blood may be coming from a non-pulmonary source (ie, the upper airway or the gastrointestinal tract) should be considered. This distinction can be difficult and may require an otolaryngological or gastrointestinal evaluation. (See",
"      <a class=\"local\" href=\"#H11003737\">",
"       'Causes of massive hemoptysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous causes of massive hemoptysis that originates in the lower respiratory tract. Many are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef62661 \" href=\"UTD.htm?36/43/37565\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11003737\">",
"       'Causes of massive hemoptysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchiectasis, tuberculosis, bronchogenic carcinoma, and various lung infections are still believed to be the most common causes of massive hemoptysis. (See",
"      <a class=\"local\" href=\"#H4654462\">",
"       'Bronchiectasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11003744\">",
"       'Tuberculosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4654544\">",
"       'Bronchogenic carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11003758\">",
"       'Fungal infections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11003765\">",
"       'Other lung infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is controversial whether bronchitis alone is sufficient to cause massive hemoptysis. Many clinicians believe that coagulopathy or other contributing factors must be present for massive hemoptysis to occur in the setting of bronchitis. (See",
"      <a class=\"local\" href=\"#H11004547\">",
"       'Bronchitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic lung diseases, bone marrow transplantation and chemotherapy, pulmonary arteriovenous malformations, mitral stenosis, pulmonary emboli, and iatrogenic complications are also potential causes of massive hemoptysis. (See",
"      <a class=\"local\" href=\"#H11003786\">",
"       'Immunologic lung diseases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4653942\">",
"       'Chemotherapy and bone marrow transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11003793\">",
"       'Cardiac and vascular diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/1\">",
"      Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/2\">",
"      Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. Clin Chest Med 1994; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/3\">",
"      Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. Arch Intern Med 1991; 151:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/4\">",
"      Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. Arch Intern Med 1989; 149:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/5\">",
"      Knott-Craig CJ, Oostuizen JG, Rossouw G, et al. Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg 1993; 105:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/6\">",
"      Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/7\">",
"      Mal H, Rullon I, Mellot F, et al. Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest 1999; 115:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/8\">",
"      Porter DK, Van Every MJ, Anthracite RF, Mack JW Jr. Massive hemoptysis in cystic fibrosis. Arch Intern Med 1983; 143:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/9\">",
"      Rasmussen, V. On haemoptysis, especially when fatal, in its anatomical and clinical aspects. Edinburgh Med J 1968; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/10\">",
"      Albelda SM, Talbot GH, Gerson SL, et al. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis 1985; 131:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/11\">",
"      Pea L, Roda L, Boussaud V, Lonjon B. Desmopressin therapy for massive hemoptysis associated with severe leptospirosis. Am J Respir Crit Care Med 2003; 167:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/12\">",
"      Miller RR, McGregor DH. Hemorrhage from carcinoma of the lung. Cancer 1980; 46:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/13\">",
"      McGuinness G, Beacher JR, Harkin TJ, et al. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest 1994; 105:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/14\">",
"      M&uuml;ller NL, Miller RR. Diffuse pulmonary hemorrhage. Radiol Clin North Am 1991; 29:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/15\">",
"      Primack SL, Miller RR, M&uuml;ller NL. Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features. AJR Am J Roentgenol 1995; 164:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/16\">",
"      Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994; 106:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26838/abstract/17\">",
"      Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998; 158:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15663 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26838=[""].join("\n");
var outline_f26_13_26838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11004209\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11003158\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11003737\">",
"      CAUSES OF MASSIVE HEMOPTYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4654462\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11003744\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11003758\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11003765\">",
"      Other lung infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4654544\">",
"      Bronchogenic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11004547\">",
"      Bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11003786\">",
"      Immunologic lung diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4653942\">",
"      Chemotherapy and bone marrow transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11003793\">",
"      Cardiac and vascular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11004209\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/15663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/15663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/43/37565\" title=\"table 1\">",
"      Causes of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/29/14812\" title=\"table 2\">",
"      Etiology of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/42/28332\" title=\"table 3A\">",
"      Features of hemorrhage I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/26/38316\" title=\"table 3B\">",
"      Features of hemorrhage II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29558?source=related_link\">",
"      Overview of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=related_link\">",
"      Overview of pulmonary disease in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26839="Dextromethorphan and quinidine: Drug information";
var content_f26_13_26839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextromethorphan and quinidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/41/42644?source=see_link\">",
"    see \"Dextromethorphan and quinidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10952132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nuedexta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10953347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nuedexta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10952135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      N-Methyl-D-Aspartate Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11280864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pseudobulbar affect:",
"     </b>",
"     Oral: One capsule once daily for 7 days, then increase to 1 capsule twice daily; reassess patient periodically to determine if continued use is necessary",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11280865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment not required for mild or moderate renal impairment; not studied with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11280866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment not required for mild or moderate hepatic impairment; however, an increase in adverse reactions is observed with moderate hepatic dysfunction; not studied with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11280872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nuedexta&trade;: Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11280868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Administer twice-daily doses every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10952136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pseudobulbar affect (PBA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16149599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nuedexta&trade; may be confused with Neulasta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11280746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (5%), flatulence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: GGT increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (4%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11280708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dextromethorphan, quinidine, quinine, mefloquine, or any component of the formulation; concomitant use with quinidine or other medications containing quinidine, quinine, or mefloquine; history of quinine-, mefloquine-, or quinidine-induced thrombocytopenia; hepatitis; bone marrow depression; or lupus-like syndrome; concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor; patients with prolonged QT interval, congenital QT syndrome, or history of torsade de pointes; patients with heart failure; concurrent use of drugs that prolong the QT interval and are metabolized by CYP2D6 (eg, pimozide, thioridazine); patients with complete AV block without an implanted pacemaker or patients at high risk of complete AV block",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11280724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects; use caution in patients with myasthenia gravis or other conditions which may be affected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dizziness: May cause dizziness; use caution in patients with motor impairment or history of falls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Quinidine has been associated with severe hepatotoxic reactions including granulomatous hepatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Agranulocytosis, angioedema, bronchospasm, lupus-like syndrome, rash or other hypersensitivity reactions may be associated with use. Use is contraindicated in patients with quinidine-, quinine-, or mefloquine-induced lupus-like syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombocytopenia: Immune-mediated thrombocytopenia (severe or fatal) may be associated with quinidine use. Unless clearly not drug related, discontinue immediately; continued use may be associated with an increase in fatal hemorrhage. Thrombocytopenia generally resolves within a few days of discontinuation. Therapy should not be restarted in sensitized patients. Use is contraindicated in patients with prior history of immune-mediated thrombocytopenia associated with structurally related drugs (eg, quinine, mefloquine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Concomitant use of moderate or strong CYP3A4 inhibitors may increase quinidine levels and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval. Quinidine inhibits CYP2D6; concomitant use with CYP2D6 substrates may cause an accumulation of concomitantly administered drug and/or reduce active metabolite formation, decreasing their safety and/or efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolonging agents: Use caution with medications which may further prolong the QT interval or cause cardiac arrhythmias. Dose-dependent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation may occur. Monitor patients at risk following the first dose. Discontinue if arrhythmia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serotonin syndrome: Symptoms associated with serotonin syndrome such as agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans); especially with higher dextromethorphan doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use caution in patients with left ventricular hypertrophy or left ventricular dysfunction which are more common in patients with chronic hypertension, coronary artery disease or history of stroke; risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation may be increased. Use is contraindicated in patients with prolonged QT interval, congenital QT syndrome, or history of torsade de pointes, patients with heart failure, complete AV block without an implanted pacemaker or patients at high risk of complete AV block. Correct hypokalemia or hypomagnesemia prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established with severe hepatic impairment; increased serum concentrations may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established with severe renal impairment; increased serum concentrations may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP2D6 poor metabolizers: Use with caution in patients who are poor metabolizers of CYP2D6 metabolized drugs. Quinidine in this combination product is used to inhibit CYP2D6 in order to increase plasma concentrations of dextromethorphan. In patients who are poor metabolizers, this effect would not be significant; however, adverse events related to quinidine may still be observed. Genotyping should be considered in patients considered to be at risk of quinidine toxicity prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dementia: Has not shown to be safe or effective in other types of commonly occurring emotional labilities (eg,  Alzheimer&rsquo;s disease and other dementias)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Periodically reassess the need for treatment; spontaneous improvement of PBA may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abuse/misuse:  Patients with a history of drug abuse should be monitored closely for signs of abuse/misuse of Nuedexta&trade; (eg, development of tolerance, increase in dose, or drug-seeking behavior). Abuse of dextromethorphan may cause brain damage, cardiac arrhythmia, loss of consciousness, or death.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of QuiNIDine. Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: QuiNIDine may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Felodipine; Nisoldipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: QuiNIDine may increase the serum concentration of Cardiac Glycosides.  Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of QuiNIDine. Management: Consider alternatives to cimetidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May enhance the QTc-prolonging effect of QuiNIDine. Crizotinib may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: QuiNIDine may increase the serum concentration of Dabigatran Etexilate.  Management: Canadian (but not U.S.) prescribing information recommends dosing dabigatran 2 hours prior to quinidine, and limiting dabigatran VTE prevention dose post hip/knee replacement to 150 mg/day in patients receiving quinidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: QuiNIDine may increase the serum concentration of Dalfampridine.  Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and quinidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: QuiNIDine may increase the serum concentration of Dextromethorphan.  Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydrocodeine: QuiNIDine may diminish the analgesic effect of Dihydrocodeine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrocodone: QuiNIDine may decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of QuiNIDine. Management: Consider separating doses of kaolin and quinidine by at least 2 hours in order to reduce the risk of interaction. Monitor for decreased therapeutic effects of quinidine if kaolin is simultaneously coadministered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of QuiNIDine. Management: Consider alternatives to quinidine in patients with acute lurasidone overdose.  If quinidine treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of QuiNIDine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: QuiNIDine may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QuiNIDine. Mifepristone may increase the serum concentration of QuiNIDine. Management: Avoid quinidine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: QuiNIDine may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: QuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the adverse/toxic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of QuiNIDine. Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline; Vilazodone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine. Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: QuiNIDine may enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): QuiNIDine may enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11280764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol as CNS effects may be enhanced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Avoid grapefruit juice (may increase levels of quinidine). Avoid tonic water (contains quinine).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11280704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11280705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies using this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11280706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11280707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quinidine is excreted in breast milk; excretion of dextromethorphan is not known",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11280769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nuedexta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-10 mg (60): $717.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11280870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     QT interval 3-4 hours after the first dose in patients at risk for QTc prolongation; potassium and magnesium prior to and during therapy; CBC, liver and renal function tests; periodically assess risk factors for arrhythmias during treatment; periodically reassess the need for treatment (spontaneous improvement of PBA may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11280767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dextromethorphan may relieve the symptoms of PBA by binding to sigma-1 receptors in the brain which may be involved in behavior, however the exact mechanism of action is not known. Quinidine is used to block the rapid metabolism of dextromethorphan, thereby increasing serum concentrations. The dose of quinidine in this combination product provides serum concentrations 1% to 3% of those needed to treat cardiac arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11280784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Bioavailability of dextromethorphan increased ~20-fold when administered with quinidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Dextromethorphan: 60% to 70%; Quinidine: 80% to 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Dextromethorphan: Hepatic via CYP2D6 to dextrorphan (active); Quinidine: Hepatic via CYP3A4 to 3-hydroxyquinidine (active) and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Dextromethorphan: 13 hours in extensive metabolizers; Quinidine: 7 hours in extensive metabolizers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Dextromethorphan: 3-4 hours; Quinidine: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Miller RG, Jackson CE, Kasarskis EJ, et al, \"Practice Parameter Update: The Care of the Patient With Amyotrophic Lateral Sclerosis: Multidisciplinary Care, Symptom Management, and Cognitive/Behavioral Impairment (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2009, 73(15):1227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/13/26839/abstract-text/19822873/pubmed\" id=\"19822873\" target=\"_blank\">",
"        19822873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schiffer R and Pope LE, \"Review of Pseudobulbar Affect Including a Novel and Potential Therapy,\"",
"      <i>",
"       J Neuropsychiatry Clin Neurosci",
"      </i>",
"      , 2005, 17(4):447-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/13/26839/abstract-text/16387982/pubmed\" id=\"16387982\" target=\"_blank\">",
"        16387982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16087 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-01FC61200C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26839=[""].join("\n");
var outline_f26_13_26839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952132\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10953347\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952135\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280864\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280865\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280866\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280872\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280868\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952136\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16149599\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280746\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280708\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280724\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299166\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304568\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280764\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280704\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280705\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280706\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280707\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280769\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322873\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280870\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280767\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11280784\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/41/42644?source=related_link\">",
"      Dextromethorphan and quinidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26840="Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis";
var content_f26_13_26840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Curtis A Pettaway, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26840/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/13/26840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H282027073\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the penis is a rare malignancy that typically presents as a painless lump or ulcer on the penis. The vast majority consist of primary epithelial squamous cell carcinoma. The diagnosis is made based upon biopsy of the lesion.",
"   </p>",
"   <p>",
"    The epidemiology and risk factors for penile cancer, staging, and prognosis are reviewed here. The clinical presentation, pathologic features, diagnosis, and treatment of penile cancer are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=see_link\">",
"     \"Carcinoma of the penis: Clinical presentation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link\">",
"     \"Carcinoma of the penis: Surgical and medical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027080\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the penis are rare in the United States, Europe, and other industrialized countries, but are more common in less developed areas of the world, such as parts of Africa, Asia, and South America. In the United States, penile carcinoma accounts for less than one percent of cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This translates into approximately 1600 new cases and 310 deaths due to penile cancer annually [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/3\">",
"     3",
"    </a>",
"    ]. However, in parts of Africa, Asia, and South America, penile cancer accounts for approximately 10 to 20 percent of all malignancies in men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penile cancer is typically a disease of older men and rates increase steadily with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/2\">",
"     2",
"    </a>",
"    ]. The mean age at diagnosis is 60 years, though penile cancer is seen in men less than 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of penile cancer varies by race [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In a study profiling invasive squamous cell carcinoma of the penis, 4967 men diagnosed between 1998 and 2003 were identified through the Surveillance, Epidemiology and End Results (SEER) program with the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rate (per 100,000 men) of squamous cell carcinoma of the penis is comparable between white and black men (0.81 versus 0.82, respectively; rate ratio [RR] 1.01, 95% CI 0.90-1.13).",
"     </li>",
"     <li>",
"      Compared to white men,",
"      <span class=\"nowrap\">",
"       Asian/Pacific",
"      </span>",
"      Islander men had a 55 percent lower incidence rate of penile carcinoma (0.37; RR 0.45, 95% CI 0.35-0.58).",
"     </li>",
"     <li>",
"      There is a higher incidence rate among Hispanic men compared to non-Hispanic men (RR 1.72, 95% CI 1.56-1.88).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027087\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors affect the risk of developing penile cancer or a precursor lesion. In one series, 137 men with penile cancer and 606 men without cancer were interviewed to ascertain risk factors for in situ and invasive penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8\">",
"     8",
"    </a>",
"    ]. Men who developed penile cancer were more often single, never married (odds ratio [OR] 2.5, 95% CI 1.1-5.6), and were circumcised at an older age (mean age, 38 versus 20 years).",
"   </p>",
"   <p>",
"    Additional risk factors for penile carcinoma include medical conditions affecting the penis, phimosis, infection with human papillomavirus (HPV), and HIV infection. These and other factors are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027094\">",
"    <span class=\"h2\">",
"     Medical conditions of the penis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following medical conditions involving the penis are associated with an increased risk of penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior history of genital warts (OR 7.6, 95% CI 4.3-13.5).",
"     </li>",
"     <li>",
"      Prior history of urinary tract infection (OR 1.7, 95% CI 1.1-2.7).",
"     </li>",
"     <li>",
"      Penile tear (OR 5.2, 95% CI 3.1-8.7). Among men circumcised in childhood the risk was twofold greater (OR 2.1, 95% CI 1.0-4.7); among men never circumcised, however, it was over 12-fold higher (OR 12.5, 95% CI 5.0-30.5).",
"     </li>",
"     <li>",
"      History of a chronic penile rash lasting one month or longer (OR 3.2, 95% CI 1.5-6.8).",
"     </li>",
"     <li>",
"      Prior penile injury (OR 3.5, 95% CI 2.5-8.5).",
"     </li>",
"     <li>",
"      Known urethral stricture (OR 2.0, 95% CI 1.1-3.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027101\">",
"    <span class=\"h2\">",
"     Phimosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phimosis is a circumferential fibrosis of preputial tissue that leads to narrowing and an inability to retract the penile foreskin over the glans penis. The presence of phimosis is associated with a 7 to 10-fold higher risk of penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although men not circumcised in childhood are at an increased risk of penile cancer, at least one study suggests that this risk is mediated by the presence of phimosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 127 men with penile cancer and 671 men without penile cancer (serving as the control group), major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lack of circumcision was associated with a twofold increased risk of penile cancer (odds ratio [OR] 2.3, 95% CI 1.3-4.1).",
"     </li>",
"     <li>",
"      Among uncircumcised men, a history of phimosis increased the risk of penile cancer (OR 11.4, 95% CI 5.0-25.9).",
"     </li>",
"     <li>",
"      The risk of penile cancer was not elevated among uncircumcised men who did not report a history of phimosis (OR 0.5, 95% CI 0.1-2.5), though the study was underpowered to evaluate this association.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027115\">",
"    <span class=\"h2\">",
"     Human papillomavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of human papillomavirus (HPV) DNA can be identified in 30 to 50 percent of all penile carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In a systematic review that included 1466 men with penile carcinomas, 47 percent of cases were associated with HPV, with the majority associated with HPV-16 (60 percent) or HPV-18 (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, HPV infection in the foreskins of otherwise healthy men without penile cancer ranges from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The impact of HPV on prognosis is discussed below. (See",
"    <a class=\"local\" href=\"#H282027164\">",
"     'Prognosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=see_link&amp;anchor=H282022467#H282022467\">",
"     \"Carcinoma of the penis: Clinical presentation and diagnosis\", section on 'Molecular alterations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link&amp;anchor=H3#H3\">",
"     \"Virology of human papillomavirus infections and the link to cancer\", section on 'Association with malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027122\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of penile cancer is approximately eightfold higher in HIV-infected men compared to that in non-HIV-infected men. However, penile carcinoma is not considered an AIDS-defining malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism underlying this observation is unclear. Although HIV may be directly responsible, the increased incidence of penile cancer in this population may be mediated by HPV. HIV infection is associated with an increased incidence of HPV infection, which may be due to lifestyle risk factors for acquiring both viruses or may be caused by the host responses to these viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506368#H1560506368\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Anogenital cancer and premalignant lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626002\">",
"    <span class=\"h2\">",
"     Smegma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smegma is a cheesy-like substance produced by glands located within the inner surface of the foreskin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/18\">",
"     18",
"    </a>",
"    ]. Smegma begins to form in the first few days of life as the result of desquamation of epithelial cells in the preputial sac. In addition, secretions from preputial glands also contribute to smegma formation. Although smegma has been shown to be carcinogenic in animal models, it is not clear whether it is a carcinogen in humans or an independent risk factor for penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027129\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors associated with penile cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tobacco exposure &mdash; Tobacco exposure (ie, smoking or chewing tobacco) is associated with an increased risk of penile cancer in a dose dependent fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8,9,20,21\">",
"       8,9,20,21",
"      </a>",
"      ]. In population-based case control studies, smokers were 3 to 4.5 times more likely to have penile cancer compared to nonsmokers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The association between smoking and penile cancer is independent of known confounding factors (such as sexual history) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cigarette smoke may increase the likelihood of penile cancer by inhibiting the function of antigen-presenting Langerhans cells, with a subsequent detrimental effect on immune system surveillance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/22\">",
"       22",
"      </a>",
"      ]. Alternatively, HPV infection, chronic penile irritation, or phimosis may act synergistically with cigarette smoking to promote malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Psoralen and ultraviolet A photochemotherapy (PUVA) &mdash; Patients treated with PUVA have an increased incidence of penile cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/20,23\">",
"       20,23",
"      </a>",
"      ]. In a prospective study of 892 men treated with PUVA, 14 patients (2 percent) developed SCC of the penis or scrotum [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/23\">",
"       23",
"      </a>",
"      ]. This was approximately 60 times higher than the expected incidence in the general population. Furthermore, the risk was increased in those exposed to higher levels of PUVA.",
"     </li>",
"     <li>",
"      Zoophilia &mdash; In one study from South America, 118 men with penile cancer was compared to 374 men without penile cancer seen in the same clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/10\">",
"       10",
"      </a>",
"      ]. In multivariate analysis, sex with animals was associated with a twofold higher risk for penile cancer (OR 2.07, 95% CI 1.21-3.52). &nbsp;",
"     </li>",
"     <li>",
"      There is no association between sexual orientation and risk of penile cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027136\">",
"    <span class=\"h1\">",
"     STAGING OF PENILE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tumor Node Metastasis (TNM) staging system is used for staging carcinoma of the penis (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"UTD.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ). This system was revised in 2010, and is supported by both the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All men with penile cancer require careful examination of the penis and palpation of the inguinal lymph nodes. The need for surgical staging of the inguinal nodes is subsequently determined based upon characteristics of the penile tumor (ie, grade, stage, lymphovascular invasion) and the presence of palpable inguinal lymph nodes. Computed tomography (CT) is usually not indicated for newly diagnosed patients without palpable inguinal adenopathy. (See",
"    <a class=\"local\" href=\"#H282027157\">",
"     'Assessment for distant metastatic (M) disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027143\">",
"    <span class=\"h2\">",
"     Tumor (T) assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination (by visual inspection and palpation) is required to evaluate the primary lesion. When the depth or extent of tumor infiltration cannot be determined by clinical exam, magnetic resonance imaging (MRI) may help identify invasion into the corpora cavernosum or spongiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information about the primary tumor is used in treatment planning, especially when organ preserving strategies are being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027150\">",
"    <span class=\"h2\">",
"     Regional node (N) assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile cancer initially spreads through the lymphatics, with the initial site of involvement being the inguinal nodes, followed sequentially by the pelvic and then retroperitoneal nodes. Therefore, the accurate assessment of the regional lymph nodes is essential for both prognosis and the proper management of patients, since resection of small volume pathologically involved regional lymph nodes can be curative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H282027164\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unfortunately, a false negative clinical examination of the inguinal region can occur in 9 to 60 percent of patients, depending on primary tumor pathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For men presenting with clinical adenopathy, those with large body mass index, and men who have had prior inguinal procedures, we perform imaging because of the limited usefulness of the physical exam in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23781913\">",
"    <span class=\"h3\">",
"     Staging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging of the inguinal nodes may be done by fine needle aspiration (FNA), dynamic sentinel node biopsy (DSNB), or superficial inguinal node dissection. A decision on the appropriate approach takes into account the clinical exam and whether or not tumor-defined risk factors for regional node involvement are present. The information obtained at staging is required to formulate an appropriate treatment plan for men with penile cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H118145918#H118145918\">",
"     \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Approach to the regional nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23781946\">",
"    <span class=\"h4\">",
"     Fine needle aspiration (FNA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNA is a minimally invasive method to evaluate for malignancy in men who present with palpable adenopathy. It is performed without local anesthesia using a 23 to 27 gauge needle. The sensitivity and specificity of FNA among men with clinically palpable nodes are over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324012657\">",
"    <span class=\"h4\">",
"     Dynamic sentinel node biopsy (DSNB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic mapping is based upon the concept that penile cancers have specific patterns of lymphatic spread and that one or more nodes (ie, sentinel nodes) are the first to be involved with metastatic disease within a given lymph node basin. This is demonstrated by injecting the penile tumor with vital blue dye and radioactive tracer followed by examination of the draining inguinal lymph nodes. If the sentinel lymph nodes are not involved, the entire basin should be free of tumor. Lymphatic mapping and dynamic sentinel node biopsy (DSNB) have been shown to reliably predict the presence of regional nodal involvement in other malignancies, such as melanoma and breast cancer.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of 17 studies reported on the detection rate and sensitivity of sentinel node biopsy in penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled sensitivity was 88 percent (95% CI, 83 to 92 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When studies that included patients with palpable nodes were excluded, the pooled sensitivity increased to 90 percent (95% CI, 85 to 94 percent).",
"     </li>",
"     <li>",
"      Incorporation of inguinal ultrasound increased the pooled sensitivity of sentinel node biopsy to 93 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the risk of a false negative result, this approach should be performed only at large centers staffed by experienced surgeons and nuclear medicine specialists. The importance of experience was demonstrated in a 2010 study that included 342 patients assessed with a modi���ed DSNB protocol from two high-volume centers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/33\">",
"     33",
"    </a>",
"    ]. In this experience, the false-negative rate was two percent (six patients with groin metastases after a negative DSNB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20463851\">",
"    <span class=\"h4\">",
"     Superficial inguinal lymph node dissection (SILND)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A superficial inguinal lymph node dissection (SILND) provides more information than biopsy of a single node or group of nodes. In addition, the possibility of not identifying the sentinel node is limited by removal of all potential sentinel nodes and the dissection is readily performed by any surgeon experienced in inguinal surgery without the need for specialized equipment.",
"   </p>",
"   <p>",
"    SILND can identify microscopic metastases in patients with a clinically normal inguinal examination, without the need for a pelvic dissection. This was demonstrated in a retrospective study of 31 men, most of whom had nonpalpable inguinal nodes at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/34\">",
"     34",
"    </a>",
"    ]. There were no recurrences among men who underwent a SILND [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/34\">",
"     34",
"    </a>",
"    ]. However, SILND was associated with a higher overall complication rate compared to DSNB (12 to 35 versus 5 to 7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186077330\">",
"    <span class=\"h2\">",
"     Staging approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the morbidity associated with inguinal lymph node dissection, we tailor our approach based on tumor-associated risk factors. This enables us to select patients at high risk for nodal involvement who would be most likely to benefit from surgical staging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367006091\">",
"    <span class=\"h3\">",
"     Clinically negative inguinal exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with a clinically negative inguinal exam, staging of the regional nodes is based upon risk estimates for occult nodal metastases.",
"   </p>",
"   <p>",
"    There are three models used for men with penile cancer: European Association of Urology (EAU), Solsona, and the Italian stratification systems. However, the accuracy of these models has not been established and there is no consensus on a preferred model. In our practice, we use the EAU risk stratification system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      European Association of Urology (EAU) system &mdash; The EAU system stratifies the risk of nodal metastases on the basis of tumor size and grade [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low risk &mdash; Men with pT1 grade 1 tumor. The risk of nodal involvement was less than 10 percent.",
"     </li>",
"     <li>",
"      Intermediate risk &mdash; Men with pT1 grade 2 tumors. The risk for nodal involvement was 9 to 12 percent.",
"     </li>",
"     <li>",
"      High risk &mdash; Men with pT1 grade 3 or pT2 to pT3 tumors. The risk for nodal involvement was over 75 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solsona risk stratification system &mdash; In the Solsona system, risk is stratified based on tumor size (",
"      <a class=\"graphic graphic_table graphicRef65885 \" href=\"UTD.htm?39/41/40605\">",
"       table 1",
"      </a>",
"      ) and tumor grade [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/38\">",
"       38",
"      </a>",
"      ]. The main difference to the EAU System is the inclusion of pT1 grade 3 and pT2 grade 1 tumors in the intermediate-risk group:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low risk &mdash; Men with pT1 grade 1 tumor. The risk of nodal involvement was 0 percent.",
"     </li>",
"     <li>",
"      Intermediate risk &mdash; Men with pT1 grade 2-3 or pT2 grade 1 tumors. The risk for nodal involvement was 33 percent.",
"     </li>",
"     <li>",
"      High risk &mdash; Men with pT2-3 grade 2-3 tumors. The risk for nodal involvement was 83 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Italian risk stratification system &mdash; An Italian group has proposed a risk-based nomogram that takes into account eight clinicopathologic factors to define risk [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/39\">",
"       39",
"      </a>",
"      ]: tumor thickness, microscopic growth pattern, Broder&rsquo;s grade, presence of vascular or lymphatic embolization, infiltration of the corpora cavernosa, corpus spongiosum or urethra, and the clinical stage of groin lymph nodes. Compared to the Solsona and EAU systems, the nomograms had better predictive accuracy, though they have yet to be externally validated and have not been widely adopted [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/39\">",
"       39",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We apply the following guidelines for staging of men with newly diagnosed penile cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &mdash; For men with pTis, Ta, or T1 grade 1 tumor (",
"      <a class=\"graphic graphic_table graphicRef65885 \" href=\"UTD.htm?39/41/40605\">",
"       table 1",
"      </a>",
"      ), we suggest surveillance rather than nodal assessment by dynamic sentinel node biopsy or inguinal node dissection. The complications of nodal evaluation outweigh the diagnostic and therapeutic benefits of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H8904433#H8904433\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Treatment of low-risk disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intermediate risk &mdash; For men with pT1 grade 2 tumors, we suggest a dynamic sentinel node biopsy. If the expertise is not available locally, we suggest a superficial inguinal node dissection. However, given the morbidity associated with an inguinal node dissection, we consider active surveillance a reasonable alternative to surgery, provided men are informed about the risk of nodal metastases and are compliant with follow-up. (See",
"      <a class=\"local\" href=\"#H324012657\">",
"       'Dynamic sentinel node biopsy (DSNB)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20463851\">",
"       'Superficial inguinal lymph node dissection (SILND)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High risk &mdash; For men with &ge;pT2 or grade 3 tumors, we suggest either dynamic sentinel node biopsy or superficial inguinal node dissection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367006098\">",
"    <span class=\"h3\">",
"     Clinically suspicious inguinal exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with evidence of palpable adenopathy on clinical exam, we and others suggest a fine needle aspiration (FNA) for pathologic assessment rather than observation or an initial course of antibiotic therapy. The FNA is sensitive and reliable enough for diagnostic purposes and will aide in further treatment planning. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with low-risk disease with clinically suspicious adenopathy but a negative FNA, we suggest an excisional biopsy for definitive diagnosis. &nbsp;",
"     </li>",
"     <li>",
"      For men with high-risk disease with clinically suspicious adenopathy but a negative FNA, we suggest a superficial inguinal node dissection. &nbsp;",
"     </li>",
"     <li>",
"      For men with a positive FNA, we proceed with definitive surgical treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men who present with bulky (node size &ge;4 cm) or unresectable lymphadenopathy should proceed with medical treatment, usually in the form of neoadjuvant chemotherapy or RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H133644063#H133644063\">",
"     \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Approach to locally advanced or unresectable disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027157\">",
"    <span class=\"h2\">",
"     Assessment for distant metastatic (M) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous spread is rare until late in the disease course, and as such, penile cancer rarely presents with distant metastases. In one series of 681 patients only 24 (4 percent) developed distant metastatic disease, and in all cases, it was late in the course following locoregional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, we do not perform routine diagnostic imaging to assess for distant metastatic disease unless the patient exhibits bulky regional nodal metastases. For such patients with bulky regional nodal metastases or those presenting with signs and symptoms of metastatic disease (eg, cachexia, pain, hepatomegaly), computed tomography of the chest, abdomen, and pelvis should be performed. In addition, routine laboratory studies should include serum calcium to evaluate for tumor-induced hypercalcemia because prompt treatment can rapidly reverse altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/42\">",
"     42",
"    </a>",
"    ]. Brain metastasis from penile carcinoma is exceedingly rare and MRI among asymptomatic patients is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027164\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of nodal involvement is the single most important prognostic factor for men with penile cancer. Some data also suggests that HPV-infection may play a prognostic role as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1737838224\">",
"    <span class=\"h2\">",
"     Nodal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important prognostic factor for survival among patients with penile cancer is the presence and extent of nodal metastases (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"UTD.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ). The five-year cancer specific survival (CSS) stratified by nodal involvement is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/43\">",
"     43",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef65885 \" href=\"UTD.htm?39/41/40605\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      pN0 (no inguinal metastases) &mdash; 85 to 100 percent",
"     </li>",
"     <li>",
"      pN1 (single metastasis) &mdash; 79 to 89 percent &nbsp;",
"     </li>",
"     <li>",
"      pN2 (bilateral or multiple inguinal metastases) &mdash; 17 to 60 percent",
"     </li>",
"     <li>",
"      pN3 (pelvic metastases) &mdash; 0 to 17 percent &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the poor prognosis associated with extranodal extension, it has been incorporated in the pN3 category (along with pelvic nodal metastases) in the 2009 American Joint Commission on Cancer (AJCC) staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of both of these factors was shown in one series of 102 patients with node-positive disease. Of 21 patients with pelvic node involvement, all had succumbed to disease within three years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/44\">",
"     44",
"    </a>",
"    ]. In the same series, extranodal extension was seen in the inguinal region in 54 men. These patients had a significantly lower rate of five year survival compared to compared to those without evidence of extranodal extension (9 versus 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1737838181\">",
"    <span class=\"h2\">",
"     Impact of HPV-infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of HPV DNA may be associated with improved disease free survival. However, the impact of HPV infection on prognosis in men with penile cancer remains uncertain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 82 men with penile cancer, HPV DNA was detected in 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/11\">",
"       11",
"      </a>",
"      ]. Although HPV positive tumors were less likely to be associated with lymphatic tumor embolization, there was no difference in either the presence of lymph node metastases or in the 10-year survival rate (68 versus 69 percent in HPV-negative and HPV-positive patients).",
"     </li>",
"     <li>",
"      A separate study of 171 patients reported the presence of high-risk HPV in 29 percent of tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26840/abstract/12\">",
"       12",
"      </a>",
"      ]. The presence of high-risk HPV DNA in penile carcinoma was associated with significantly improved disease specific survival at five years (hazard ratio for mortality 0.14, 95% CI 0.03-0.63; 93 versus 78 percent in HPV-negative patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282027207\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancers of the penis are rare in the United States, Europe, and other industrialized countries, but occur at a higher frequency in developing countries. (See",
"      <a class=\"local\" href=\"#H282027080\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Penile cancer is typically a disease of older men and rates increase steadily with age, although men of any age may be affected. (See",
"      <a class=\"local\" href=\"#H282027080\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of risk factors are associated with an increased risk of penile cancer, including medical conditions of the penis, phimosis, human papillomavirus (HPV) infection, and HIV infection. (See",
"      <a class=\"local\" href=\"#H282027087\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Tumor Node Metastasis (TNM) staging system is used for staging carcinoma of the penis. (See",
"      <a class=\"local\" href=\"#H282027136\">",
"       'Staging of penile cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All men with penile cancer require examination of the penis and inguinal region. Radiologic exam by computed tomography or MRI is suggested for patients presenting with clinical adenopathy or those with large body mass index because of the limited usefulness of the physical exam in that setting. (See",
"      <a class=\"local\" href=\"#H282027143\">",
"       'Tumor (T) assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical assessment of nodes in men with penile cancer is based on their risk at diagnosis as defined by the tumor stage, grade, LVI, and the presence of palpable adenopathy. (See",
"      <a class=\"local\" href=\"#H282027150\">",
"       'Regional node (N) assessment'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      For men with no palpable adenopathy on clinical exam (see",
"      <a class=\"local\" href=\"#H367006091\">",
"       'Clinically negative inguinal exam'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest surveillance for men with low-risk disease (eg, pTa, pTis, or pT1 grade 1, no poorly differentiated cancer, no LVI [ie, AJCC stage pT1a]), rather than nodal assessment by dynamic sentinel node biopsy (DSNB) or superficial inguinal node dissection (SILND) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The complications of nodal evaluation outweigh the diagnostic and therapeutic benefits of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H8904433#H8904433\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Treatment of low-risk disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We perform nodal staging for men with intermediate risk disease (eg, pT1 grade 2 [mainly] or pT2 grade 1 [rare scenario] [ie, AJCC stage pT1b-pT2]). Either a DSNB or SILND can be performed with the choice based on local expertise. However, for well informed and compliant patients, close observation at three month intervals may be a reasonable alternative.",
"     </li>",
"     <li>",
"      We also perform an initial staging DSNB or SILND for men with high risk disease (pT2-3 grade 2-3 [AJCC stage pT2-T3]) depending on local expertise. These men are not appropriate candidates for surveillance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For men with palpable adenopathy on clinical exam, we and others suggest a fine needle aspiration (FNA) for pathologic assessment rather than observation or an initial course of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H367006098\">",
"       'Clinically suspicious inguinal exam'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with low-risk disease with clinically suspicious adenopathy but a negative FNA, we perform an excisional biopsy for definitive diagnosis. &nbsp;",
"     </li>",
"     <li>",
"      For men with high-risk disease with clinically suspicious adenopathy but a negative FNA, we suggest a superficial inguinal node dissection. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H9746503#H9746503\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Clinically suspicious examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with a positive FNA, we suggest a therapeutic inguinal node dissection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H9746503#H9746503\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Clinically suspicious examination'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who present with bulky (node &ge;4 cm) or unresectable lymphadenopathy, we suggest neoadjuvant chemotherapy rather than surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prior to treatment, these men should undergo a further staging work-up to define the extent of disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=see_link&amp;anchor=H133644063#H133644063\">",
"       \"Carcinoma of the penis: Surgical and medical treatment\", section on 'Approach to locally advanced or unresectable disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence and extent of inguinal lymph node metastases is the strongest predictor of cancer specific survival. (See",
"      <a class=\"local\" href=\"#H282027164\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40891110\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Donald F Lynch, who contributed to previous versions of this topic review card.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/1\">",
"      Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, et al. Incidence trends in primary malignant penile cancer. Urol Oncol 2007; 25:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/2\">",
"      Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008; 113:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/4\">",
"      Ornellas AA. Management of penile cancer. J Surg Oncol 2008; 97:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/5\">",
"      Hegarty PK, Kayes O, Freeman A, et al. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/6\">",
"      Favorito LA, Nardi AC, Ronalsa M, et al. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 2008; 34:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/7\">",
"      Rippentrop JM, Joslyn SA, Konety BR. Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology, and end results program. Cancer 2004; 101:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/8\">",
"      Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005; 116:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/9\">",
"      Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/10\">",
"      Zequi Sde C, Guimar&atilde;es GC, da Fonseca FP, et al. Sex with animals (SWA): behavioral characteristics and possible association with penile cancer. A multicenter study. J Sex Med 2012; 9:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/11\">",
"      Bezerra AL, Lopes A, Santiago GH, et al. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001; 91:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/12\">",
"      Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006; 119:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/13\">",
"      Miralles-Guri C, Bruni L, Cubilla AL, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2012; 61:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/15\">",
"      Varma VA, Sanchez-Lanier M, Unger ER, et al. Association of human papillomavirus with penile carcinoma: a study using polymerase chain reaction and in situ hybridization. Hum Pathol 1991; 22:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/16\">",
"      Grussendorf-Conen EI, Meinhof W, de Villiers EM, Gissmann L. Occurrence of HPV genomes in penile smears of healthy men. Arch Dermatol Res 1987; 279 Suppl:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/17\">",
"      Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/18\">",
"      Hunter JS, Saslawsky M. Penile mass in a 53-year-old patient. Obstruction of smegma-producing glands. Am Fam Physician 2005; 72:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/19\">",
"      Van Howe RS, Hodges FM. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol 2006; 20:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/20\">",
"      Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000; :189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/21\">",
"      Harish K, Ravi R. The role of tobacco in penile carcinoma. Br J Urol 1995; 75:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/22\">",
"      Holly EA, Palefsky JM. Factors related to risk of penile cancer: new evidence from a study in the Pacific Northwest. J Natl Cancer Inst 1993; 85:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/23\">",
"      Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990; 322:1093.",
"     </a>",
"    </li>",
"    <li>",
"     Penis. In: American Joint Committee on Cancer Staging Manual, Springer, New York 2009. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/25\">",
"      Petralia G, Villa G, Scardino E, et al. Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erection. Radiol Med 2008; 113:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/26\">",
"      Feldman AS, McDougal WS. Long-term outcome of excisional organ sparing surgery for carcinoma of the penis. J Urol 2011; 186:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/27\">",
"      Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol 2010; 183:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/28\">",
"      S&aacute;nchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 2004; 22:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/29\">",
"      Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/30\">",
"      Delacroix SE Jr, Pettaway CA. Therapeutic strategies for advanced penile carcinoma. Curr Opin Support Palliat Care 2010; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/31\">",
"      Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 2006; 97:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/32\">",
"      Sadeghi R, Gholami H, Zakavi SR, et al. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol 2012; 187:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/33\">",
"      Graafland NM, Lam W, Leijte JA, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol 2010; 58:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/34\">",
"      Spiess PE, Izawa JI, Bassett R, et al. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 2007; 177:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/35\">",
"      Solsona E, Algaba F, Horenblas S, et al. EAU Guidelines on Penile Cancer. Eur Urol 2004; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/36\">",
"      Hughes BE, Leijte JA, Kroon BK, et al. Lymph node metastasis in intermediate-risk penile squamous cell cancer: a two-centre experience. Eur Urol 2010; 57:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/37\">",
"      Heyns CF, Mendoza-Vald&eacute;s A, Pompeo AC. Diagnosis and staging of penile cancer. Urology 2010; 76:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/38\">",
"      Solsona E, Iborra I, Rubio J, et al. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol 2001; 165:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/39\">",
"      Ficarra V, Novara G, Boscolo-Berto R, et al. How accurate are present risk group assignment tools in penile cancer? World J Urol 2009; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology. Penile Cancer. Version 1.2012. file://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/41\">",
"      Ornellas AA, Kinchin EW, N&oacute;brega BL, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol 2008; 97:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/42\">",
"      Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/43\">",
"      Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology 2010; 76:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26840/abstract/44\">",
"      Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3002 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26840=[""].join("\n");
var outline_f26_13_26840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H282027207\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027073\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027080\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027087\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027094\">",
"      Medical conditions of the penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027101\">",
"      Phimosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027115\">",
"      Human papillomavirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027122\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626002\">",
"      Smegma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027129\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027136\">",
"      STAGING OF PENILE CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027143\">",
"      Tumor (T) assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027150\">",
"      Regional node (N) assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23781913\">",
"      - Staging techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23781946\">",
"      Fine needle aspiration (FNA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H324012657\">",
"      Dynamic sentinel node biopsy (DSNB)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20463851\">",
"      Superficial inguinal lymph node dissection (SILND)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186077330\">",
"      Staging approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367006091\">",
"      - Clinically negative inguinal exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367006098\">",
"      - Clinically suspicious inguinal exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282027157\">",
"      Assessment for distant metastatic (M) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027164\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1737838224\">",
"      Nodal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1737838181\">",
"      Impact of HPV-infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282027207\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40891110\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3002\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3002|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/41/40605\" title=\"table 1\">",
"      TNM staging penile cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=related_link\">",
"      Carcinoma of the penis: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/4/41033?source=related_link\">",
"      Carcinoma of the penis: Surgical and medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26841="Evaluation of purpura in children";
var content_f26_13_26841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of purpura in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26841/contributors\">",
"     Leslie Raffini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26841/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26841/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/13/26841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding under the skin or into mucosal membranes is called purpura and may be an innocent finding related to mild childhood trauma or may be the presenting sign of a life threatening disease. Purpura can be subdivided based on size into petechiae (",
"    <a class=\"graphic graphic_picture graphicRef73905 \" href=\"UTD.htm?14/62/15330\">",
"     picture 1",
"    </a>",
"    ) and ecchymoses (",
"    <a class=\"graphic graphic_picture graphicRef59402 \" href=\"UTD.htm?15/20/15681\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/1\">",
"     1",
"    </a>",
"    ]. Pinpoint areas (less than 2 mm) of hemorrhage, which are reddish-purple lesions are called petechiae (",
"    <a class=\"graphic graphic_picture graphicRef73905 \" href=\"UTD.htm?14/62/15330\">",
"     picture 1",
"    </a>",
"    ), while larger confluent lesions are referred to as ecchymoses (",
"    <a class=\"graphic graphic_picture graphicRef59402 \" href=\"UTD.htm?15/20/15681\">",
"     picture 2",
"    </a>",
"    ). Ecchymoses are commonly called bruises. In some cases, ecchymoses may be tender or raised. In contrast to other erythematous or vascular skin lesions, purpuric lesions do not blanch when pressure is applied to the skin.",
"   </p>",
"   <p>",
"    Careful evaluation of any patient with purpura is important for early diagnosis and treatment, particularly in children who are ill-appearing. The type, location, and extent of the purpura, along with the overall appearance of the child, will help guide the initial evaluation.",
"   </p>",
"   <p>",
"    This review will discuss the evaluation of purpura in children. The evaluation of bleeding in children and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura may result from disruptions in vascular integrity (trauma, infection, vasculitis, collagen disorders) or may be due to abnormalities in primary or secondary hemostasis (thrombocytopenia, abnormal platelet function, clotting factor deficiency, or abnormal clotting factor function) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complex mechanisms maintain vascular integrity and limit the flow of blood when a blood vessel is damaged:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin C and other factors that affect collagen synthesis are required for normal formation of connective tissue within the vessel walls. When a blood vessel is injured, vasoconstriction and retraction usually occur immediately and decrease the flow of blood to the affected area.",
"     </li>",
"     <li>",
"      Formation of a platelet plug, also referred to as primary hemostasis, is initiated upon injury to a blood vessel wall:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Circulating platelets recognize subendothelial collagen and von Willebrand factor, and adhere to the injured area.",
"     </li>",
"     <li>",
"      Following adhesion to the vascular subendothelium, platelets are rapidly activated, resulting in the release of platelet granules.",
"     </li>",
"     <li>",
"      This granule release attracts other circulating platelets, which bind to activated platelets causing platelet aggregation, and the formation of a platelet plug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The platelet plug alone is not sufficient, and requires the second phase of hemostasis to form a stable fibrin clot. This second phase is initiated when tissue factor (which is exposed on the endothelial cell after injury) binds to factor VII. This proteolytic TF-VIIa complex activates factor X to Xa and factor IX to IXa, initiating a series of cascading reactions whose central purpose is to generate thrombin from prothrombin (II) at the site of injury. There are multiple coagulation proteins that are necessary for this cascade. Thrombin can then cleave fibrinogen to fibrin, which is cross-linked and forms a clot. These reactions occur on the phospholipid surface of platelets. The coagulation cascade is shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DISRUPTIONS IN VASCULAR INTEGRITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is the most common etiology of purpura in children.",
"   </p>",
"   <p>",
"    Non-blanching purpura from unintentional trauma vary in size from a few millimeters to several centimeters and are frequently located over extensor surfaces of the lower legs, bony prominences including the knees and elbows, and the forehead. It is not possible to reliably predict the age of an ecchymoses based on its color. However, red, blue, or purple bruises suggest recent lesions. &nbsp;Yellow, brown, or green bruises tend to be older, healing lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H12#H12\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Stages of healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the presence of purpura on the face, back, upper arms, or soft tissue areas including buttocks, genitals, and upper thigh may suggest the possibility of intentional trauma. Bruising is the most common presenting feature of physical abuse in children. Other patterns of bruising that are suggestive of non-accidental trauma are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57478 \" href=\"UTD.htm?1/58/1963\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H9#H9\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Bruises'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura fulminans (PF) is an acute life-threatening disorder that most commonly occurs following infection with Neisseria meningitidis, but may also occur in association with other infections (eg, varicella, Group A Streptococcus, Streptococcus pneumoniae). It is a result of microvascular thrombosis that leads to tissue necrosis, skin infarction and hemorrhage. Patients with PF are extremely ill-appearing, with fever, hypotension, and bleeding. Laboratory evidence of disseminated intravascular coagulation (DIC) is often present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of meningococcal infection\", section on 'Purpura fulminans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link\">",
"     \"Disseminated intravascular coagulation in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lesions of PF have a characteristic appearance, which helps to distinguish them from other purpuric lesions. Erythema is followed by central areas of blue or black hemorrhagic necrosis with a surrounding erythematous border (",
"    <a class=\"graphic graphic_picture graphicRef52107 \" href=\"UTD.htm?30/28/31168\">",
"     picture 3",
"    </a>",
"    ). The lesions are painful and indurated.",
"   </p>",
"   <p>",
"    Viral infections, including parvovirus, adenovirus, and enterovirus, and Rickettsial infections have also been associated with the development of purpuric lesions in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Petechiae and purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (HSP [IgA vasculitis (IgAV)]) is the most common cause of vasculitis in children, occurring at a mean age of six years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical manifestations of HSP (IgAV) are due to IgA1 deposition in blood vessel walls and the renal mesangium. Cutaneous purpura is an essential component in the diagnosis of HSP (IgAV) and is characterized by palpable purpuric lesions 2 to 10 mm in diameter that often coalesce (",
"    <a class=\"graphic graphic_picture graphicRef63367 graphicRef72094 \" href=\"UTD.htm?26/46/27367\">",
"     picture 4A-B",
"    </a>",
"    ). The purpura tend to be concentrated on the buttocks and lower extremities. Other clinical manifestations of HSP (IgAV) include arthritis (commonly of the knees and ankles), abdominal pain with or without gastrointestinal bleeding, and nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drug-induced vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous drugs have been associated with vasculitis and purpura. These include sulfonamides, penicillins,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/4\">",
"     4",
"    </a>",
"    ]. Drug induced vasculitis usually develops within 7 to 21 days of starting the drug and may be confined to the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neonatal purpura fulminans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal purpura fulminans usually occurs on the first day of life and is caused by congenital severe deficiency of protein C or protein S. Affected infants present with ecchymoses, extensive venous and arterial thromboses, laboratory evidence of disseminated intravascular coagulation, and extremely low levels of protein C antigen (less than 1 percent of normal).",
"   </p>",
"   <p>",
"    Administration of exogenous protein replacement (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"     Protein C concentrate",
"    </a>",
"    or fresh frozen plasma) appears to be critical for the treatment of neonatal purpura fulminans, while",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    and antiplatelet agents are ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H10#H10\">",
"     \"Protein C deficiency\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe acquired deficiency of the anticoagulant proteins, protein C and protein S, may also present with non-infectious purpura fulminans or in association with infectious disseminated intravascular coagulopathy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vitamin C deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary deficiency of Vitamin C (scurvy) is relatively rare in developed countries. It may occur in individuals with severely restricted diets (anorexia, neurodevelopmental delay,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperalimentation without vitamin C supplementation). Vitamin C deficiency results in impaired collagen synthesis.",
"   </p>",
"   <p>",
"    The typical pathologic manifestations of vitamin C deficiency are noted in collagen-containing tissues and in organs and tissues such as skin, cartilage, dentin, osteoid, and capillary blood vessels. Scurvy may present with gum bleeding, petechiae or ecchymoses. In addition, the prominence of hair follicles on the thighs and buttocks and the eruption of coiled, fragmented hair with a characteristic corkscrew appearance are specific features of vitamin C deficiency. Petechiae found on the skin have a characteristic pale halo ring around a central erythematous core (",
"    <a class=\"graphic graphic_picture graphicRef64172 \" href=\"UTD.htm?33/17/34067\">",
"     picture 5",
"    </a>",
"    ). These lesions heal rapidly after the administration of vitamin C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H54#H54\">",
"     \"Overview of water-soluble vitamins\", section on 'Vitamin C (ascorbic acid)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ehlers-Danlos syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ehlers-Danlos syndrome (EDS) is the name given to a group of inherited disorders that involve genetic defects in collagen and connective-tissue synthesis and structure. This heterogeneous group is characterized by joint hypermobility, cutaneous fragility, and hyperextensibility. Fragility of dermal skin is common, with frequent bruises and delayed wound healing. In some cases, abnormal blood vessel structure causes capillary hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISORDERS OF HEMOSTASIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions which result in either decreased platelet number or abnormal platelet function may present with purpura. These conditions may be inherited or acquired. The normal platelet count is",
"    <span class=\"nowrap\">",
"     &gt;150,000/mm3.",
"    </span>",
"    In the majority of situations, thrombocytopenia is acquired. In general, patients do not develop bleeding until the platelet count drops below",
"    <span class=\"nowrap\">",
"     20,000/mm3,",
"    </span>",
"    unless there is associated trauma or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may be a result of increased platelet destruction, decreased platelet production, or sequestration (",
"    <a class=\"graphic graphic_table graphicRef61161 \" href=\"UTD.htm?30/54/31596\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Immune thrombocytopenia (ITP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) is one of the most common causes of thrombocytopenia in children. This immune mediated disorder is characterized by the sudden development of petechiae and ecchymoses in an otherwise healthy child, although symptoms may occasionally develop more gradually. Epistaxis occurs in 10 to 20 percent, and although more serious bleeding may occur, it is uncommon. ITP occurs most frequently in children between the ages of one to five years, but also occurs in older children and adults. In young children, the development of ITP is often preceded by a mild viral illness. The diagnosis of ITP is based upon two clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated thrombocytopenia, with otherwise normal blood counts and peripheral blood smear",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No clinically apparent associated conditions that may cause thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic uremic syndrome (HUS) is a disease that primarily affects young children and is characterized by the triad of thrombocytopenia, microangiopathic anemia, and acute renal failure. Patients may rarely manifest purpura. HUS can be divided into two forms based upon clinical presentation: Typical HUS is most common and usually follows a prodromal infectious disease, most commonly diarrhea, and less frequently an upper respiratory infection. This syndrome is classically associated with Escherichia coli serotype O157:H7. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Thrombocytopenia'",
"    </a>",
"    .) Atypical HUS is a heterogeneous disorder characterized by the absence of diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Thrombotic thrombocytopenic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura (TTP) is most common in adults, but is occasionally seen in children. The classic pentad includes thrombocytopenia, microangiopathic hemolytic anemia, fever, renal dysfunction, and neurologic abnormalities. It is a usually a result of deficiency of the ADAMTS-13 protease, which is responsible for cleaving von Willebrand factor (vWf) multimers. Without this cleavage, ultra large vWf multimers circulate, stimulating microvascular platelet thrombi which cause microangiopathic hemolytic anemia and thrombocytopenia. In adults, TTP is most often a result of antibody mediated destruction of ADAMTS-13. Less commonly, an inherited form of TTP may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may be an early manifestation of disseminated intravascular coagulation (DIC). (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Disseminated intravascular coagulation (DIC)'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link\">",
"     \"Disseminated intravascular coagulation in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bone marrow infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases associated with decreased amounts of functional bone marrow also may present with thrombocytopenia and purpura. Most notable in this group in children are acute leukemia and neuroblastoma. In the majority of cases, hematologic abnormalities other than thrombocytopenia are also present (eg, anemia, leukopenia, or leukocytosis), but occasionally a decrease in the platelet count may be the only abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Peripheral blood abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Neonatal alloimmune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal alloimmune thrombocytopenia (NAIT) occurs when fetal platelets contain an antigen inherited from the father that the mother lacks. The mother forms IgG class antiplatelet antibodies against the \"foreign\" antigen; these cross the placenta and destroy fetal platelets, resulting in fetal and neonatal thrombocytopenia. Plasma levels of thrombopoietin in these patients are normal because the megakaryocytes and platelets that are produced bind to this growth factor. In contrast to Rh sensitization, NAIT often develops in the first pregnancy of an at-risk couple.",
"   </p>",
"   <p>",
"    NAIT can result in severe thrombocytopenia in the fetus because platelet antigens form early in gestation and maternal antibodies cross the placenta in early midtrimester. The most serious complication is intracranial hemorrhage, which occurs in approximately 10 to 20 percent of affected newborns; one-quarter to one-half of these occur in utero. The risk of severe thrombocytopenia and intracranial hemorrhage is greater in alloimmune than in autoimmune thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link\">",
"     \"Neonatal thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Inherited thrombocytopenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;True hereditary isolated thrombocytopenia is an extremely rare cause of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H27#H27\">",
"     \"Neonatal thrombocytopenia\", section on 'Genetic disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=see_link&amp;anchor=H17#H17\">",
"     \"Causes of thrombocytopenia in children\", section on 'Genetic causes of impaired thrombopoiesis'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital amegakaryocytic thrombocytopenia is characterized by severe thrombocytopenia that is present at birth and may be associated with skeletal abnormalities.",
"     </li>",
"     <li>",
"      The thrombocytopenia with absent radii (TAR) syndrome has an autosomal recessive inheritance. The thrombocytopenia in TAR is variable in severity, but tends to improve over time.",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome is an X-linked recessive disorder characterized by thrombocytopenia, eczema, and immunodeficiency. Infants with Wiskott-Aldrich may present with thrombocytopenic purpura beginning in the newborn period. Shortened platelet survival in this disease comes from an intrinsic platelet abnormality.",
"     </li>",
"     <li>",
"      Patients with inherited giant-platelets may have Bernard-Soulier syndrome or one of the MYH-9 related syndromes (May-Hegglin anomaly, Sebastian, Fechtner, or Epstein). The MYH-9 related disorders may be associated with sensorineural hearing loss, glomerulonephritis and cataracts. The bleeding phenotype is variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drug induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous drugs have been reported to cause thrombocytopenia due to the formation of antibodies directed against platelets with resultant increased platelet destruction. The drugs causing immune-mediated thrombocytopenia that are most commonly used in children include sulfa compounds (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ), valproic acid, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, drugs may also cause thrombocytopenia as a result of decreased platelet production. Any drug capable of causing general bone marrow suppression can produce thrombocytopenia (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ). Valproic acid causes dose-related suppression of platelet production in addition to sporadic, immune-mediated platelet destruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired aplastic anemia in children and young adults\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bone marrow failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic Anemia (AA) is a rare disorder of hematopoiesis characterized by pancytopenia and bone marrow hypoplasia. The majority of cases are acquired and this appears to be an immune mediated condition. In some patients with the acquired form, AA is preceded by hepatitis, viral infection, or toxin exposure; though there is no identifiable etiologic agent in the majority. Patients with one of the rare, congenital bone marrow failure syndromes (Fanconi's anemia, dyskeratosis congenital, cartilage-hair hypoplasia) often have other abnormalities on physical exam. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H12#H12\">",
"     \"Acquired aplastic anemia in children and young adults\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"     \"Inherited aplastic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Sequestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly that comes from numerous causes (eg, portal hypertension, storage diseases) can result in sequestration of platelets and thrombocytopenia. The spleen is markedly enlarged and very firm in these disorders. Purpura that comes from platelet sequestration alone is rare because the platelet count usually does not fall below",
"    <span class=\"nowrap\">",
"     40,000/mm3.",
"    </span>",
"    Bleeding may occur, however, when the platelet sequestration is associated with liver disease and clotting abnormalities. Platelet sequestration and consumption also can occur in large hemangiomas (Kasabach Merritt syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Inherited platelet function abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited platelet function disorders are an uncommon cause of bleeding. There are several disorders which range in severity. The most severe, but also quite rare, are Glanzmann thrombasthenia and Bernard-Soulier syndrome.",
"   </p>",
"   <p>",
"    In Glanzmann thrombasthenia, the platelet count is normal and there is a deficiency of the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    complex. Bernard-Soulier syndrome results from a deficiency of platelet glycoprotein protein complex",
"    <span class=\"nowrap\">",
"     GP1b/IX/V,",
"    </span>",
"    which mediates the initial interaction of platelets to the subendothelial components via the von Willebrand protein. In Bernard-Soulier syndrome the platelet count may be decreased, but, characteristically, the platelets are large, often the size of red blood cells, and may be missed because most automatic counters do not count them as platelets. Both Bernard-Soulier syndrome and Glanzmann thrombasthenia are characterized by life-long bleeding.",
"   </p>",
"   <p>",
"    Other more common, but less severe, platelet function abnormalities include storage pool defects (eg, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome) or mild secretion defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Acquired platelet function abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs are the most common cause of acquired platelet dysfunction.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    is the best known of the drugs that cause platelet dysfunction. A single dose of aspirin can irreversibly alter platelet function by blocking the normal pathway of thromboxane-induced platelet aggregation. Non-steroidal anti-inflammatory drugs (NSAIDs), such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , have a similar mechanism of action, but the effects are reversible and the disruption of platelet function is less pronounced. Platelet dysfunction also has been associated with antihistamines, phenothiazines, valproic acid and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=see_link\">",
"     guaifenesin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with uremia often develop platelet function abnormalities that may result in purpura. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clotting factor deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura can be the presenting symptom of a congenital or acquired deficiency of coagulation factors. The most commonly encountered congenital deficiencies are von Willebrand disease, hemophilia A (factor VIII deficiency), and hemophilia B (factor IX deficiency). Although the latter two disorders have an X-linked recessive mode of inheritance, the de novo appearance of coagulopathy is not uncommon, particularly in children with severe hemophilia A (factor VIII activity less than 1 percent). Therefore, a family history of affected males may be helpful in establishing the diagnosis of hemophilia, but the absence of such a history does not eliminate this diagnostic possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand disease (VWD) is the most common congenital bleeding disorder, present in approximately 1 percent of the population. It is actually a collection of disorders characterized by either quantitative or qualitative abnormalities of von Willebrand factor (vWf). VWD affects males and females equally and is generally inherited as an autosomal dominant trait with variable penetrance. VWD should be suspected in patients with a history of easy bruising, mucous membrane bleeding (epistaxis, menorrhagia), or prolonged bleeding after a surgical procedure (eg, post-tooth extraction). In contrast to hemophilia, joint and muscle bleeds are very uncommon in VWD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hemophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia, the most common inherited severe bleeding disorder, is an X-linked disorder that affects males of all ethnic groups. Hemophilia A (deficiency of factor VIII) occurs in approximately 1 in 5000 live male births and is five to six times more common than Hemophilia B (deficiency of factor IX). The severity of hemophilia is classified according to the amount of circulating functional clotting factor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lt;1 percent &ndash; Severe disease",
"     </li>",
"     <li>",
"      1 to 5 percent &ndash; Moderate disease",
"     </li>",
"     <li>",
"      &gt;5 percent &ndash; Mild disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe hemophilia experience frequent spontaneous bleeding episodes, in contrast to those with moderate or mild hemophilia in whom trauma or surgery is usually required to provoke hemorrhage. Although bleeding can occur in almost any site, hemarthrosis (intra-articular bleeding) is the most common clinical manifestation, and the ankles, knees, and elbows are most frequently affected.",
"   </p>",
"   <p>",
"    Children with hemophilia often come to medical attention when they develop purpura either spontaneously or after mild trauma. The ecchymoses in boys with hemophilia are often quite pronounced and palpable for the degree of trauma. The diagnosis of hemophilia should also be entertained in newborns who develop excessive bleeding after circumcision and in infants with prolonged bleeding from lacerations of the lip, tongue, or frenulum. Prompt recognition of the disorder at this early age allows for careful surveillance, appropriate treatment, and early genetic counseling for parents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other congenital factor deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;While VWD and hemophilia A and B represent the majority of inherited bleeding disorders, hereditary deficiencies of other clotting factors may also be encountered. Deficiencies of the following factors result in clinical bleeding: II, V, X, VII, XI. XIII, and fibrinogen. These are all autosomal traits, and are usually symptomatic only in patients with homozygous deficiencies. Most patients with the above deficiencies will have an abnormal PT or aPTT. The diagnosis requires specific factor assays. Patients with factor XIII deficiency will have normal screening tests and can be diagnosed with a factor XIII functional assay that assays clot solubility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link\">",
"     \"Rare (recessively inherited) coagulation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Vitamin K deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin K is an essential fat-soluble vitamin that is required for the post-translational gamma-carboxylation of several of the clotting factors. The clotting factors that are vitamin K dependent are: II, VII, IX, and X. Deficiency of vitamin K leads to low levels of these clotting factors which may present with purpura or more systemic bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of vitamin K\", section on 'Deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemorrhagic disease of the newborn, with clinical manifestations that range from purpura to intracranial hemorrhage, may occur in infants who do not receive prophylactic vitamin K at birth. This important step in normal newborn care may be overlooked when infants are born at home, or when problems develop in the delivery room and vitamin K is not given. The classic form presents in the first week of life, and the late form presents between two weeks and six months of life. The deficiency is the result of inadequate stores of vitamin K due to maternal deficiency or exclusive breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of vitamin K\", section on 'Vitamin K deficient bleeding in the newborn'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin K deficiency may occur in older children with malabsorption or chronic diarrhea. Ingestion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    or long-acting superwarfarin rat poisons (eg, brodifacoum), which interferes with the metabolism of vitamin K, may also present with purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of clotting factors are produced in the liver. As a result, impaired hepatic synthesis, due to either inherited or acquired liver dysfunction may lead to a coagulopathy and purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation (DIC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC is a complex consumptive coagulopathy that is characterized by diffuse intravascular activation of coagulation resulting in thrombocytopenia and clotting factor deficiencies. It is associated with a variety of infectious and noninfectious disease states (",
"    <a class=\"graphic graphic_table graphicRef59455 \" href=\"UTD.htm?15/6/15468\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thrombocytopenia from shortened platelet survival may occur due to fibrin deposition and platelet consumption. In addition, the intravascular consumption of clotting factors may cause purpura because of factor depletion and, in severe cases, may lead to widespread, rapidly progressing purpuric lesions (purpura fulminans) associated with thrombosis or emboli.",
"   </p>",
"   <p>",
"    Infections are the most common cause of DIC in children (",
"    <a class=\"graphic graphic_table graphicRef59455 \" href=\"UTD.htm?15/6/15468\">",
"     table 3",
"    </a>",
"    ). Although other signs of serious illness are usually present in the child with purpura caused by DIC, fever and purpura may be the only significant findings in the early stages of severe bacterial infections such as meningococcemia. Further investigations and appropriate therapy should proceed rapidly in such instances. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Infection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Disseminated intravascular coagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with purpura must combine speed and skill. Purpura can be the initial sign of a life threatening meningococcal infection, requiring immediate treatment, or the first sign of child abuse, requiring patient, thorough investigation. The initial approach should be dictated by the general appearance of the child and the presenting vital signs. A well-appearing child with purpura and normal vital signs can be approached with less urgency than a febrile, lethargic child with purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;By taking into account the patient's age, sex, clinical presentation, past medical history, and family history, the most likely causes of purpura can usually be determined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; Serious infection is an important cause of purpura in children and is usually associated with fever.",
"     </li>",
"     <li>",
"      Age of patient &ndash; Serious congenital bleeding disorders usually present in the first year of life.",
"     </li>",
"     <li>",
"      Sex of patient &ndash; Hemophilia is X-linked. Thus, it is only seen in boys. Von Willebrand is autosomal dominant and is seen with equal frequency in boys and girls.",
"     </li>",
"     <li>",
"      Onset of symptoms &ndash; The patient's recent and past medical history should be reviewed carefully with the parents and child. Acute onset of purpura after a recent viral illness or immunization is consistent with an acquired disorder such as ITP. Recurrent purpura since infancy, however, suggests an inherited abnormality of platelets or clotting factors.",
"     </li>",
"     <li>",
"      Location and type of purpura &ndash; The site and type of bleeding manifestation may be helpful in establishing the alteration in the hemostatic mechanisms (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 4",
"      </a>",
"      ). Petechiae are most commonly seen in patients with thrombocytopenia and platelet disorders, mucosal bleeding (menorrhagia, epistaxis) is common in platelet disorders and von Willebrand disease, and bleeding into the joints (hemarthroses) is common in patients with hemophilia.",
"     </li>",
"     <li>",
"      Prior bleeding history &ndash; Specific inquiries about past surgeries (including circumcision), dental extractions, or significant trauma should be made because the absence of bleeding under these conditions would be unusual in most inherited disorders of even moderate severity. When previous bleeding has occurred, the site of bleeding may be helpful in establishing the alteration in the hemostatic mechanisms.",
"     </li>",
"     <li>",
"      Family history of bleeding &ndash; The family history should be reviewed for purpura or bleeding disorders. A positive family history in male relatives on the maternal side suggests factor VIII or factor IX deficiency. A history of bleeding or bruising in numerous family members of both sexes suggests a condition with dominant inheritance such as von Willebrand's disease. As noted earlier, however, a negative family history does not preclude the diagnosis of von Willebrand disease or hemophilia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hemophilia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recent medications &ndash; The clinician should note exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      and other drugs known to affect platelet function. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Drug induced thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exploratory or intentional overdose of prescription anticoagulant or rat poison (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      or superwarfarin) ingestion &ndash; In general, oral intake of small amounts of rat poison (eg, single handful of superwarfarin product) or prescription anticoagulant would be unlikely to result in purpura. Thus, patients with purpura in whom these ingestions are confirmed have likely had a large ingestion. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Vitamin K deficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H16#H16\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Superwarfarin poisoning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dietary history &ndash; Patients with severe malnutrition or restricted diets may be at risk for scurvy or vitamin K deficiency.",
"     </li>",
"     <li>",
"      Past medical history &ndash; Patients with underlying conditions such as uremia, hepatic disease, congenital heart disease, and malabsorption are predisposed to a coagulopathy that may present with purpura and bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General examination &ndash; The overall appearance of a child will help guide further management. Patients who have purpuric lesions and are ill-appearing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemodynamically unstable need to be rapidly assessed to determine the underlying etiology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin &ndash; The child should be examined carefully to assist in the diagnosis of the specific bleeding disorder and to evaluate hidden areas of hemorrhage. The distribution and size of purpura should be noted. It is not possible to reliably predict the age of an ecchymoses based on its color. &nbsp;However, red, blue, or purple bruises suggest recent lesions. &nbsp;Yellow, brown, or green bruises tend to be older, healing lesions. [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/5\">",
"       5",
"      </a>",
"      ]. Ecchymotic lesions may take weeks to resolve.",
"      <br/>",
"      <br/>",
"      Petechiae indicate disorders associated with thrombocytopenia or platelet dysfunction. Clotting disorders typically cause mucosal bleeding or ecchymoses without petechiae (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Bruising in a recognizable pattern, such as a loop mark (",
"      <a class=\"graphic graphic_picture graphicRef69125 \" href=\"UTD.htm?21/30/21985\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef79721 \" href=\"UTD.htm?16/5/16479\">",
"       picture 7",
"      </a>",
"      ), ligature mark, belt or hand print (",
"      <a class=\"graphic graphic_picture graphicRef78258 \" href=\"UTD.htm?26/55/27505\">",
"       picture 8",
"      </a>",
"      ), indicates child abuse. Bruises in multiple stages of healing in areas atypical for unintentional trauma are also suspicious (",
"      <a class=\"graphic graphic_picture graphicRef76016 \" href=\"UTD.htm?31/43/32433\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H9#H9\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Bruises'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Purpura localized to the lower body (buttocks, legs, ankles), with or without joint swelling in the hands or feet, suggests Henoch-Sch&ouml;nlein purpura (HSP [IgA vasculitis (IgAV)]).",
"     </li>",
"     <li>",
"      Lymph nodes &ndash; Lymphadenopathy may be present in certain malignancies (leukemias) or viral infections (infectious mononucleosis, CMV) that can present with purpura.",
"     </li>",
"     <li>",
"      Abdominal examination &ndash; Hepatomegaly may signal an underlying hepatic disorder that can cause a coagulopathy.",
"      <br/>",
"      <br/>",
"      Splenomegaly can be seen in infectious mononucleosis, leukemia, hepatic disease, and the storage diseases.",
"     </li>",
"     <li>",
"      Extremities and joints &ndash; Inflammation or synovial thickening of the large joints is consistent with the hemarthroses seen in hemophilia or the swollen, painful joints associated with Henoch-Schonlein purpura (IgA vasculitis).",
"     </li>",
"     <li>",
"      Neurologic evaluation &ndash; Complete neurologic assessment is mandatory when there is suspicion of head trauma in the face of a bleeding diathesis. The eyes should be examined for the presence of conjunctival, scleral, or retinal hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial screening tests in a patient with purpura should include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26841/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count (CBC), including platelet count and peripheral smear",
"     </li>",
"     <li>",
"      Prothrombin time (PT)",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time (aPTT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CBC establishes abnormalities in platelet number, the presence of abnormalities in other hematologic cell lines (eg, anemia, leukopenia), and provides evidence for intravascular hemolysis. The PT tests the extrinsic clotting pathway (factors VII, IX, II, X, V, fibrinogen). The aPTT tests the intrinsic pathway (factors HWMK, kallikrein, XII, XI, IX, VIII, II, X, V, fibrinogen) (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"     figure 1",
"    </a>",
"    ). Details of testing, including nonmedical causes for abnormal results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the child with bleeding symptoms\", section on 'Relevant laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bleeding time is not routinely recommended in children. It is subject to significant variation based on the experience of the technician and cooperation of the patient.",
"   </p>",
"   <p>",
"    In patients with a suspected bleeding disorder, discriminating laboratory studies should be obtained based on the results of the initial screening tests and the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef67121 \" href=\"UTD.htm?36/13/37084\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inspection of blood smear (screening for bone marrow diseases and platelet clumping)",
"     </li>",
"     <li>",
"      Mean platelet volume (elevated in destructive causes, low in Wiskott-Aldrich syndrome)",
"     </li>",
"     <li>",
"      Bone marrow aspiration (rarely necessary)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PT and aPTT prolonged and thrombocytopenia (suspect DIC):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fibrinogen",
"     </li>",
"     <li>",
"      D-dimer or fibrin split products",
"     </li>",
"     <li>",
"      Peripheral smear inspection for RBC fragments (schistocytes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged PT and aPTT (normal platelet count):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factor assays: II (prothrombin), V, VII, VIII and fibrinogen to help distinguish between hepatic dysfunction and vitamin K deficiency",
"     </li>",
"     <li>",
"      Hepatic enzymes and serum albumin to assess hepatic function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged aPTT only:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inhibitor screen (50:50 mixing study of patient's and normal plasma)",
"     </li>",
"     <li>",
"      If aPTT fully corrects:",
"      <br/>",
"      <br/>",
"      Specific factors: VIII, IX, XI, XII, VW Ag, VW Activity",
"     </li>",
"     <li>",
"      If partial or no correction after mixing study:",
"      <br/>",
"      <br/>",
"      Inhibitor is present",
"      <br/>",
"      <br/>",
"      Confirmatory test for the presence of a lupus anticoagulant with a platelet neutralizing procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged PT only:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factor VII level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial CBC, smear, PT, and aPTT normal:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Qualitative platelet defect suspected. There is controversy regarding the usefulness of the PFA-100, a screening assay for platelet function. If a platelet defect is strongly suspected, consider platelet aggregometry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H8#H8\">",
"       \"Platelet function testing\", section on 'Platelet aggregometry'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      von Willebrand disease (VWD) suspected. The clinician should obtain factor VIII:C, von Willebrand factor (vWf; VIIIR:Ag), ristocetin cofactor or von Willebrand factor activity, and vWf multimeric analysis. The normal ranges of these tests depend on the patient's ABO blood group type; values fluctuate over time and may periodically be normal in affected individuals. Thus, diagnosis may require repeated testing to make the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     ALGORITHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach to the evaluation of a child with purpura helps guide the workup and identify the appropriate treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef78063 \" href=\"UTD.htm?8/35/8752\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Appears ill",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with purpura who are ill-appearing or febrile require rapid evaluation and treatment for serious hemorrhage, disseminated intravascular coagulopathy, or infection. Patients with abnormal vital signs warrant emergent attention and stabilization of the airway, breathing, and circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A directed history, physical exam, and pertinent laboratory studies should target likely underlying etiologies including serious trauma, child abuse, and bacterial sepsis (meningococcemia). Empiric antibiotic treatment (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum initial dose: 2 grams and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum initial dose: 1 gram in previously healthy child) is usually warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinogen, D-dimer or fibrin split products (FSP), peripheral smear, and liver testing (albumin and liver enzymes) should be performed in addition to screening coagulation studies (CBC, PT, aPTT). (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Appears well",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-appearing children with purpura should undergo a detailed history, physical examination, and screening coagulation studies (CBC, PT, aPTT) to establish the most likely diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe, isolated thrombocytopenia (PT, aPTT normal) who are well-appearing and previously healthy with physical exam abnormalities consisting solely of petechiae",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ecchymoses, usually have immune-mediated thrombocytopenia (ITP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of thrombocytopenia are suggested by the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young infants with thrombocytopenia may have an inherited thrombocytopenia or alloimmune thrombocytopenia due to maternal antibodies.",
"     </li>",
"     <li>",
"      Those patients with thrombocytopenia and other abnormalities on CBC (eg, anemia, leukopenia) may have hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, malignancy (leukemia, neuroblastoma), or bone marrow failure (congenital or acquired).",
"     </li>",
"     <li>",
"      Children with thrombocytopenia and evidence for microangiopathic hemolytic anemia (eg, schistocytes on peripheral blood smear) may have HUS or TTP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Normal platelet count, abnormal PT or aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with purpura and abnormal initial coagulation tests require further investigation to determine the etiology of the abnormal PT or aPTT. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Laboratory evaluation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the child with bleeding symptoms\", section on 'Relevant laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Normal platelet count, PT, and aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in whom trauma (unintentional or intentional) is the primary etiology of purpura will have normal screening tests in the absence of massive hemorrhage or transfusion. Petechiae are unusual as a primary presentation of trauma except in traumatic asphyxia. These screening tests are also usually normal in patients with vascular causes of purpura. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H9#H9\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Bruises'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some patients with von Willebrand disease or platelet function disorders will have normal screening tests. Further laboratory studies (platelet aggregation testing and von Willebrand testing) is often necessary to diagnose these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura may result from disruptions in vascular integrity (trauma, infection, vasculitis, collagen disorders) or due to abnormalities in primary or secondary hemostasis (thrombocytopenia, abnormal platelet function, or clotting factor deficiency). A systematic approach to the evaluation of a child with purpura helps guide the work-up and identify the appropriate treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef78063 \" href=\"UTD.htm?8/35/8752\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cohen A. Rash - Purpura. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher G, Henretig F (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.583.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26841/abstract/2\">",
"      Leung AK, Chan KW. Evaluating the child with purpura. Am Fam Physician 2001; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26841/abstract/3\">",
"      Saulsbury FT. Clinical update: Henoch-Sch&ouml;nlein purpura. Lancet 2007; 369:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26841/abstract/4\">",
"      ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26841/abstract/5\">",
"      Maguire S, Mann MK, Sibert J, Kemp A. Can you age bruises accurately in children? A systematic review. Arch Dis Child 2005; 90:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26841/abstract/6\">",
"      Khair K, Liesner R. Bruising and bleeding in infants and children--a practical approach. Br J Haematol 2006; 133:221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6443 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26841=[""].join("\n");
var outline_f26_13_26841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DISRUPTIONS IN VASCULAR INTEGRITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drug-induced vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neonatal purpura fulminans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vitamin C deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ehlers-Danlos syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISORDERS OF HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Immune thrombocytopenia (ITP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Thrombotic thrombocytopenic purpura",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bone marrow infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Inherited thrombocytopenias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drug induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bone marrow failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Sequestration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Inherited platelet function abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Acquired platelet function abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clotting factor deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hemophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other congenital factor deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Vitamin K deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Disseminated intravascular coagulation (DIC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      ALGORITHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Appears ill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Appears well",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Normal platelet count, abnormal PT or aPTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Normal platelet count, PT, and aPTT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6443\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6443|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/35/8752\" title=\"algorithm 1\">",
"      Pediatric purpura algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6443|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/51/32574\" title=\"figure 1\">",
"      Coagulation cascade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6443|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/62/15330\" title=\"picture 1\">",
"      Petechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/20/15681\" title=\"picture 2\">",
"      Child ecchymoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/28/31168\" title=\"picture 3\">",
"      Acute meningococcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33282\" title=\"picture 4A\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42721\" title=\"picture 4B\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/17/34067\" title=\"picture 5\">",
"      Perifollicular abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/30/21985\" title=\"picture 6\">",
"      Loopmarks acute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/5/16479\" title=\"picture 7\">",
"      Loopmarks scar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/55/27505\" title=\"picture 8\">",
"      Handprint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/43/32433\" title=\"picture 9\">",
"      Multiple bruises",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6443|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/58/1963\" title=\"table 1\">",
"      Bruises child abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/54/31596\" title=\"table 2\">",
"      Thrombocytopenia causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/6/15468\" title=\"table 3\">",
"      Causes DIC children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 4\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/13/37084\" title=\"table 5\">",
"      Test results bleeding disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25591?source=related_link\">",
"      Causes of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26842="Inherited aplastic anemia in children";
var content_f26_13_26842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited aplastic anemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Akiko Shimamura, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/13/26842/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/13/26842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic anemia (AA) is a rare disorder characterized by pancytopenia and a hypocellular bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. AA can result from either inherited or acquired causes (",
"    <a class=\"graphic graphic_table graphicRef52354 \" href=\"UTD.htm?16/15/16635\">",
"     table 1",
"    </a>",
"    ). The incidence is triphasic, with one peak in childhood at two to five years (due to inherited causes), and two peaks in adulthood, 20 to 25 years and the majority of patients presenting beyond 55 to 60 years of age (typically due to acquired causes) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1\">",
"     1",
"    </a>",
"    ]. The associated neutropenia and thrombocytopenia can lead to potentially life-threatening infections and bleeding.",
"   </p>",
"   <p>",
"    The majority of children (75 percent) with inherited bone marrow failure have an identifiable etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/4\">",
"     4",
"    </a>",
"    ]. The four major inherited causes for AA in children are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fanconi anemia",
"     </li>",
"     <li>",
"      Dyskeratosis congenita",
"     </li>",
"     <li>",
"      Shwachman-Diamond syndrome",
"     </li>",
"     <li>",
"      Amegakaryocytic thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These syndromes may present with or without physical anomalies and do not necessarily demonstrate complete pancytopenia, particularly during the early phases of disease. Acquired AA, which accounts for most cases of AA in children, is a disorder that often responds to immunosuppressive therapy (",
"    <a class=\"graphic graphic_table graphicRef70072 \" href=\"UTD.htm?7/49/7964\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The inherited aplastic anemias will be reviewed here. The acquired aplastic anemias in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"     \"Acquired aplastic anemia in children and young adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of aplastic anemia (AA) is variable and includes symptoms and signs related to cytopenia in each of the three lineages. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic manifestations secondary to thrombocytopenia",
"     </li>",
"     <li>",
"      Fatigue and pallor caused by progressive anemia",
"     </li>",
"     <li>",
"      Fever, mucosal ulcerations, and bacterial infections resulting from neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some of the inherited disorders of AA often are associated with characteristic congenital malformations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrahematologic manifestations. Although the presence of physical findings provides important clues to the underlying diagnosis of inherited marrow failure, the absence of physical anomalies does not rule out an inherited marrow failure syndrome. Many patients with inherited marrow failure syndromes fail to manifest classical physical findings.",
"   </p>",
"   <p>",
"    The complete blood count (CBC) generally shows decreased cell counts in one or more blood cell lines. For children with inherited aplastic anemias, the initial CBC findings may be mildly abnormal and involve only one cell line, particularly early in life. We suggest that children be evaluated by a pediatric hematologist if they have persistent or progressive unexplained cytopenias, particularly when associated with macrocytosis, involvement of two or more cell lines,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated with short stature or other dysmorphic clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of aplastic anemia (AA) is established by bone marrow aspiration and biopsy. The characteristic findings of AA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bone marrow is profoundly hypocellular with a decrease in all hematopoietic elements; the marrow space is predominantly composed of fat cells, lymphocytes, and marrow stroma (",
"      <a class=\"graphic graphic_picture graphicRef66353 \" href=\"UTD.htm?31/49/32530\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71042 \" href=\"UTD.htm?1/59/1976\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The residual hematopoietic cells are not malignant. Inherited marrow failure syndromes often manifest dysplastic features such as hyponucleated small megakaryocytes, multinucleated red cells, or hypolobulated and hypogranular myeloid cells. Lymphocytes may be the predominant white cell present.",
"     </li>",
"     <li>",
"      Malignant infiltrates are absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the diagnosis of AA is confirmed by biopsy, the patient should undergo a detailed evaluation for possible precipitating factors or causes of AA (",
"    <a class=\"graphic graphic_table graphicRef53126 \" href=\"UTD.htm?42/0/43019\">",
"     table 3",
"    </a>",
"    ). This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of the history including a history of exposure to medications or toxin and a family history of cytopenias, congenital anomalies or cancer predisposition. Excessive toxicity to chemotherapy or radiation may provide a clue to the underlying diagnosis of an inherited marrow failure syndrome. Either a personal or family history of pulmonary fibrosis suggests the possibility of dyskeratosis congenita.",
"     </li>",
"     <li>",
"      Physical examination looking for dysmorphic features associated with specific inherited AA or signs of other causes of pancytopenia, such as infections, malignancies, or rheumatologic disorders",
"     </li>",
"     <li>",
"      Serologic testing for viruses associated with AA",
"     </li>",
"     <li>",
"      Serum folate and B12 levels",
"     </li>",
"     <li>",
"      Tests for specific causes of AA such as chromosomal breakage testing with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C or diepoxybutane (DEB) screening to detect Fanconi anemia is important for all pediatric patients. Telomere length measurements to screen for dyskeratosis congenita may be considered as clinically indicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fanconi anemia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13\">",
"       'Dyskeratosis congenita'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an inherited form of marrow failure (Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, or amegakaryocytic thrombocytopenia) is diagnosed, genetic testing is recommended for all siblings of the proband, because early diagnosis critically impacts clinical management and allows for early intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FANCONI ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fanconi anemia (FA) is the most common form of inherited AA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1\">",
"     1",
"    </a>",
"    ]. It is an autosomal recessive or X-linked disorder that occurs in all races and ethnic groups. The heterozygote frequency may be 1:300 in the United States and Europe and is increased to 1:100 in Ashkenazi Jews and South African Afrikaans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple genes appear to be responsible for FA. Fifteen complementation groups (FA-A to FA-P) have been identified, and a corresponding gene has been cloned for each [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/5-15\">",
"     5-15",
"    </a>",
"    ]. The genes are widely dispersed throughout the genome, including the X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Several of these genes are tumor suppressor genes. The function of Fanconi anemia proteins is to maintain genomic stability, mainly through the repair of DNA interstrand crosslinks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gene responsible for FA-A, which occurs in 60 to 65 percent of patients with Fanconi anemia, is located on chromosome 16q24.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. FA-C and FA-G are the next most common subtypes, each occurring in 10 percent of patients with FA. The normal FA gene product may contribute to the maintenance of genomic stability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/15\">",
"       15",
"      </a>",
"      ], control of apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/20\">",
"       20",
"      </a>",
"      ], oxidant sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/21-24\">",
"       21-24",
"      </a>",
"      ], and response to cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. Restoration of the expression of the normal FA protein in cells from patients with FA normalizes cellular growth and corrects their sensitivity to chromosomal breakage in the presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C.",
"     </li>",
"     <li>",
"      The FA gene FANCD1 is identical to BRCA2, one of the breast cancer susceptibility genes involved with DNA repair. Disruption of this repair process may result in the chromosomal abnormalities and propensity to malignancy (eg, medulloblastoma, head and neck tumors, acute leukemia) that are characteristic of Fanconi anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. It may also contribute to the susceptibility to cancer (eg, breast, ovary, pancreas) seen in some kindreds with Fanconi anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. As an example, it has been suggested that biallelic inactivating mutations of some of these genes are responsible for FA, while certain monoallelic mutations confer an increased susceptibility to breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/13,15,33-35\">",
"       13,15,33-35",
"      </a>",
"      ]. Other genes that are associated with both FA and breast cancer risk include BRIP1 (also known as BACH1 and FANCJ), PALB2 (also known as FANCN), and RAD51C [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H2#H2\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'BRCA1 and BRCA2 genes'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      FA gene products participate in DNA damage response pathways involving other DNA repair proteins such as BRCA1, ATM (ataxia-telangiectasia mutated gene product), ataxia-telangiectasia kinase (ATR), and Nijmegen breakage syndrome (NBS) protein [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/7,13,15,38,39\">",
"       7,13,15,38,39",
"      </a>",
"      ]. As an example, a complex of eight FA proteins is required for monoubiquitination (binding of ubiquitin) of the FANCD2 and FANCI proteins, which allows translocation of FANCD2 to chromatin where it interacts with other DNA repair proteins. The inability of FANCD2 or FANCI to bind ubiquitin disrupts this repair process. This impairment is not seen in other inherited bone marrow failure syndromes or other chromosomal breakage syndromes (eg, NBS, Bloom syndrome, Xeroderma pigmentosa, or Werner syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FA proteins may also serve additional functions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. As an example, following DNA damage, FA proteins may play a role in promoting cell cycle arrest in the G2 phase preventing cell cycling into mitosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Other roles may include responding to oxidative stress [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/17,21-24\">",
"       17,21-24",
"      </a>",
"      ] and apoptotic stimuli such as tumor necrosis factor-alpha and interferon-gamma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/45-48\">",
"       45-48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with FA are diagnosed between six and nine years of age; the median age for boys is 6.5 years and for girls 8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 4 percent of cases are recognized between birth and one year of age, and 9 percent are diagnosed after 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,49\">",
"     1,49",
"    </a>",
"    ]. The diagnosis of Fanconi anemia may be delayed until adulthood, particularly for those patients for whom malignancy is the presenting clinical manifestation.",
"   </p>",
"   <p>",
"    Characteristic congenital malformations are present in up to 60 to 70 percent of affected children (",
"    <a class=\"graphic graphic_table graphicRef71159 \" href=\"UTD.htm?14/12/14540\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,49,50\">",
"     1,49,50",
"    </a>",
"    ]. Common malformations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short stature",
"     </li>",
"     <li>",
"      Hypopigmented spots and caf&eacute;-au-lait spots",
"     </li>",
"     <li>",
"      Abnormality of thumbs",
"     </li>",
"     <li>",
"      Microcephaly or hydrocephaly",
"     </li>",
"     <li>",
"      Hypogonadism",
"     </li>",
"     <li>",
"      Developmental delay",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remaining patients have no congenital anomalies. Although they may have short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/51\">",
"     51",
"    </a>",
"    ], normal height does not rule out the diagnosis of FA.",
"   </p>",
"   <p>",
"    Patients with FA are at high risk for developing a malignancy, particularly myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), and squamous cell carcinoma of the head and neck or vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/52\">",
"     52",
"    </a>",
"    ]. The presence of specific clonal chromosomal changes in the bone marrow may be a risk factor for leukemia in patients with FA. In one study of 53 patients, 18 had amplification of chromosome 3q, which was associated with shorter patient survival and increased risk for development of MDS and AML [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/53\">",
"     53",
"    </a>",
"    ]. Cytogenetic clones should be interpreted within the context of the marrow morphology. Some cytogenetic clones of unclear clinical significance may remain stable or become undetectable over time. Close monitoring of the bone marrow and the blood counts is warranted in patients with marrow cytogenetic clonal abnormalities. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Malignancy may be the first manifestation of FA, so the diagnosis of FA should be considered in patients presenting with cancers at an unusually young age, who are especially sensitive to the toxic effects of chemotherapy or radiation, or a family history suggesting cancer susceptibility or inherited marrow failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematologic findings in patients with FA evolve over months to years. As an example, patients in a large series from the International Fanconi Anemia Registry (IFAR) developed cytopenia at a median age of seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients often present with mild to moderate thrombocytopenia, which may be misdiagnosed as immune thrombocytopenia (ITP). Mild leukopenia also may be seen as an initial presentation. Anemia, when detected, is often macrocytic and frequently mild on presentation (",
"    <a class=\"graphic graphic_table graphicRef57755 \" href=\"UTD.htm?14/17/14619\">",
"     table 5",
"    </a>",
"    ). As many as 70 percent of children with FA will have evidence of bone marrow failure by age 10. Hemoglobin electrophoresis usually shows increased concentrations of hemoglobin F, consistent with \"stress erythropoiesis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/54\">",
"     54",
"    </a>",
"    ].Serum alpha-fetoprotein (sAFP) levels are often elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/55\">",
"     55",
"    </a>",
"    ]. In one study, an elevated concentration for sAFP was found in 57 of 61 patients with FA and an increased value of sAFP",
"    <span class=\"nowrap\">",
"     &gt;8kIU/L",
"    </span>",
"    (62",
"    <span class=\"nowrap\">",
"     ug/L)",
"    </span>",
"    distinguished FA from other acquired or inherited bone marrow failure syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of Fanconi anemia should be considered in any patient presenting with the congenital malformations associated with FA, together with otherwise unexplained cytopenias or aplastic anemia, unexplained macrocytosis, or an affected sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/52,54,56\">",
"     52,54,56",
"    </a>",
"    ]. Fanconi anemia may also be considered in patients with cancers presenting at an unusually young age or a family history suggestive of a cancer predisposition syndrome.",
"   </p>",
"   <p>",
"    The diagnosis is made by the presence of increased chromosomal breakage in lymphocytes cultured in the presence of DNA cross-linking agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C (MMC) or diepoxybutane (DEB) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,57,58\">",
"     1,57,58",
"    </a>",
"    ]. Care must be taken to distinguish FA from other chromosomal breakage syndromes, such as NBS, that also manifest some increase in chromosomal breakage in response to MMC.",
"   </p>",
"   <p>",
"    It is common to see more than one affected child in a family. In one series, 30 percent of families had two affected children, and consanguinity was noted in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/56\">",
"     56",
"    </a>",
"    ]. All siblings of affected patients should be tested for increased chromosomal breakage as the phenotype is variable within families. Thus, a sibling with FA may lack malformations even though the proband has congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the FA gene mutations are known for a family, genetic sequence analysis may detect mothers who are carriers of FA genes. Prenatal diagnosis of affected children is also possible. Prenatal testing can be performed on cells obtained by chorionic villus sampling, amniocentesis, or cordocentesis for known affected families. Prenatal screening for FA-C in Ashkenazi Jews is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link&amp;anchor=H26#H26\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\", section on 'Fanconi anemia type C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of FA has been made, further evaluation for additional organ system involvement is recommended and may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine &mdash; Blood studies including thyroid function studies, and levels of cortisol, fasting glucose, and insulin. Bone density also may be decreased in patients with FA. Some patients may require further evaluation if they have clinically significant short stature or pubertal delay. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"       \"Diagnostic approach to short stature\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ophthalmology &mdash; Ophthalmologic examination.",
"     </li>",
"     <li>",
"      Otolaryngology &mdash; Audiology exam at diagnosis. Regular ENT examinations every 6 months for patients &gt;10 years of age to screen for malignancies.",
"     </li>",
"     <li>",
"      Genitourinary system &mdash; Baseline renal ultrasound. Annual gynecologic examinations in female patients &gt;18 years of age.",
"     </li>",
"     <li>",
"      Gastrointestinal system",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management can be divided into therapy directed towards reversal of bone marrow failure and supportive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Therapy for bone marrow failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will discuss the current options to treat bone marrow failure including hematopoietic cell transplant, androgen therapy, and hematopoietic growth factors, and suggestions on when to consider each modality based upon the clinical status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455049\">",
"    <span class=\"h4\">",
"     Hematopoietic cell transplantation (HCT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT is the only currently available curative treatment for bone marrow failure. Outcomes are generally better with HLA-identical sibling donors (who do not have FA as verified by DEB or MMC testing) and in younger patients who have not yet developed complications from their bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/59-65\">",
"     59-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"     \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Long-term complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the higher risks associated with unrelated donor HCT, the decision to proceed with an unrelated donor HCT is based upon individual choice for patients who lack an HLA-matched sibling, have become refractory to medical management, who have developed severe symptomatic or transfusion-dependent cytopenias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who have evidence of evolving myelodysplastic syndrome (MDS) or leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,66-70\">",
"     1,66-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\", section on 'Matched unrelated donor HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with FA are more sensitive to the toxicities associated with transplant conditioning regimens, thus reduction of the intensity of these regimens is necessary. It is critical to exclude FA prior to HCT for aplastic anemia or malignancy to ensure that the appropriate conditioning regimen is used.",
"   </p>",
"   <p>",
"    Although HCT is curative for bone marrow failure, it does not cure other manifestations of FA and in some circumstances may increase their incidence, such as the development of solid tumor malignancies. As an example, one retrospective study reported that patients with FA who underwent HCT have a 4.4-fold higher risk of developing head and neck squamous cell carcinoma than non-transplanted patients with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/71\">",
"     71",
"    </a>",
"    ]. The incidence of solid tumors following transplant with current regimens remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455022\">",
"    <span class=\"h4\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without an HLA-matched family member and for whom transplant is not a preferred option, androgen therapy may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Only about half of patients with FA will respond to androgen therapy. It appears to be most beneficial in improving anemia, followed by thrombocytopenia, and then neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Androgens may be more effective if initiated prior to complete failure of the bone marrow. Androgen therapy may be considered when the hemoglobin (Hgb) level drops &lt;8",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    or the platelet count falls &lt;30,000 per mm3. Androgen therapy does not prevent the progression to MDS or AML. Once leukemias develop, the outcome for successful HCT may be reduced.",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"     Oxymetholone",
"    </a>",
"    is the standard recommended androgen and is started at a dose of 2 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. If the patient responds with stabilization or improvement of cell line(s), then the daily dose may be tapered to the minimum effective dose. If no response is seen after three months, oxymetholone should be discontinued. Side effects include virilization, growth spurt followed by premature closure of epiphyses, hyperactivity and behavioral changes, cholestatic jaundice and elevation of liver transaminases, hypertension, and rarely hepatic adenoma, hepatoma, and hepatic cystic disease (peliosis hepatis). While published reports on the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"     danazol",
"    </a>",
"    in Fanconi anemia are lacking, a clinical trial is currently ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455029\">",
"    <span class=\"h4\">",
"     Hematopoietic growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     Granulocyte colony-stimulating factor",
"    </a>",
"    (rhG-CSF) or granulocyte-macrophage colony-stimulating factor (rhGM-CSF) may raise the neutrophil count in most neutropenic patients, but the platelet count and Hgb concentration generally are unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].In one study, for example, 12 neutropenic patients with FA were treated with rhG-CSF (5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day initially and then every other day) for 40 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/76\">",
"     76",
"    </a>",
"    ]. All patients had an increase in their absolute neutrophil count (ANC) with 8 patients maintaining an ANC &gt;1500",
"    <span class=\"nowrap\">",
"     counts/microL,",
"    </span>",
"    four untransfused patients had an increase in hemoglobin concentration of at least 2.0",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and four had an increase in platelet count that was not maintained when the rhG-CSF dose was reduced.",
"   </p>",
"   <p>",
"    Although there are no clinical trials comparing the two growth factors, there is more clinical experience in the use of rhG-CSF. The starting dose of rhG-CSF is 5",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per day, and the dose is adjusted towards a target goal of ANC 1500 to 2000",
"    <span class=\"nowrap\">",
"     counts/microL.",
"    </span>",
"    If possible, the administration of rhG-CSF is adjusted to every other day to minimize the frequency of administration. An alternative choice is rhGM-CSF, which is started at a dose of 250",
"    <span class=\"nowrap\">",
"     micrograms/m2",
"    </span>",
"    per day. If there is no improvement in the neutrophil count after eight weeks, treatment should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1455036\">",
"    <span class=\"h4\">",
"     Consensus recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2003, therapeutic outlines for patients with FA were developed by a consensus group of experts sponsored by the Fanconi Anemia Research Fund [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/66\">",
"     66",
"    </a>",
"    ]. A follow-up consensus conference was held in 2008, and",
"    <a class=\"external\" href=\"file://www.fanconi.org/index.php/publications/guidelines_for_diagnosis_and_management\">",
"     guidelines from this conference",
"    </a>",
"    are available online [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/77\">",
"     77",
"    </a>",
"    ]. The blood count parameters provide general guidance that may be tailored depending on clinical symptoms. The recommendations are based upon the severity of marrow dysfunction (",
"    <a class=\"graphic graphic_table graphicRef57755 \" href=\"UTD.htm?14/17/14619\">",
"     table 5",
"    </a>",
"    ) and are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild bone marrow failure defined as ANC &lt;1500 but &ge;1000 per mm3, platelet count &lt;150,000 but &ge;50,000 per mm3, and Hgb level less than normal for age but &ge;8",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      Patients with mild bone marrow failure require clinical monitoring with complete blood count (CBC) including differential count at least every three months and a bone marrow biopsy and aspiration including cytogenetics yearly. If there are changes in blood counts without an apparent underlying cause (eg, infection), the frequency of monitoring is initially increased with testing of CBC every one to two months and a marrow exam every three to six months, with subsequent reduction in the frequency of testing as clinically indicated. Appropriate plans for intervention should be in place, as adverse changes may evolve rapidly.",
"     </li>",
"     <li>",
"      Moderate bone marrow failure defined as ANC between 500 to 1000 per mm3, platelet count between 30,000 to 50,000 per mm3, and Hgb level &lt;8",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      If there is an HLA-identical sibling who does not have FA confirmed by screening, consider discussion of HCT in patients with moderate bone marrow failure. For those patients with an Hgb level &lt;8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and who do not wish to proceed to HCT or are at high risk for poor HCT outcome, the use of androgen therapy may be considered. Otherwise, if the patient is asymptomatic, continue to monitor the CBC every three to four months and marrow yearly if there is no clonal abnormality. If there is a cytogenetic abnormality, the CBC initially should be monitored every one to two months and the marrow every one to six months with subsequent reduction in frequency of testing as clinically indicated. If the patient is symptomatic, supportive therapy may be needed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Supportive therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Severe bone marrow failure defined as ANC &le;500 per mm3, platelet count &le;30,000 per mm3, and Hgb level &lt;8",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      For eligible candidates, unrelated donor HCT may be considered. If transplant is not an option, androgens and hematopoietic growth factors may be given. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"       \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive therapy includes replacement therapy for each of the cell lines based upon the clinical status of the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia &mdash; Transfusion should be given when the patient is symptomatic (eg, decreased activity level, excessive fatigue, shortness of breath, and poor growth). Only red cells that have been leuko-depleted to minimize the risk of allosensitization and irradiated should be used. Directed donations by family members should be discouraged to reduce the risk of graft rejection due to alloimmunization in patients who subsequently undergo HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link\">",
"       \"Red cell transfusion in infants and children: Selection of blood products\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; Platelet transfusion is indicated in patients with severe bruising, bleeding, or undergoing invasive procedures. The use of single donor pheresis platelets minimizes exposure to multiple donors.",
"     </li>",
"     <li>",
"      Neutropenia &mdash; Patients with fever and neutropenia should be examined and cultured to determine the source of fever and receive broad spectrum antibiotics until the fever resolves or cultures are negative. There are no studies to indicate clinical benefit from routine use of prophylactic antibiotics, and their use may potentially increase the risk of fungal infections and antibiotic resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\", section on 'Aplastic anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FA are at increased risk for bone marrow failure, leukemia, or other forms of cancer (primarily squamous cell carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/52,78-80\">",
"     52,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from the IFAR, 173 of the 754 registered patients had a total of 199 neoplasms, 60 percent of which were of hematologic origin (eg, leukemia, myelodysplastic syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/52\">",
"     52",
"    </a>",
"    ]. The estimated actuarial risk of developing bone marrow failure, hematologic malignancy, or non-hematologic malignancy by age 40 was 90, 33, and 28 percent, respectively, with an 80 percent overall mortality at 40 years.",
"   </p>",
"   <p>",
"    In a retrospective cohort of 145 North American patients with Fanconi anemia, the ratio of observed to expected cancers was 4317 for vulvar cancer, 2362 for esophageal cancer, 706 for head and neck cancer, and 785 for leukemia. Cause-specific hazard for AML peaked at 1 percent per year in the second decade of life. The hazard of bone marrow transplant peaked at 4 percent at age seven. The cumulative incidence to age 48 years was 10 percent for leukemia, 11 percent for death from marrow failure, 29 percent for solid tumor, and 43 percent for bone marrow transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of head and neck squamous cell carcinoma in patients with FA is approximately 500-fold higher than that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/71,81\">",
"     71,81",
"    </a>",
"    ]. Risk factors for head and neck squamous cell carcinoma include chronic graft versus host disease following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/71,81\">",
"     71,81",
"    </a>",
"    ], and an increased susceptibility of patients with FA to carcinogenesis induced by the human papillomavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. In addition to the head and neck, squamous cell carcinoma can occur in the cervix, vulva, pharynx, esophagus, and liver of patients with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Other solid tumors can be associated with FA, such as brain tumors and Wilms tumor, particularly in patients with the",
"    <span class=\"nowrap\">",
"     FANCD1/BRCA2",
"    </span>",
"    subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DYSKERATOSIS CONGENITA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyskeratosis congenita (DC) is an inherited disorder characterized by marrow failure, cancer predisposition, and additional somatic abnormalities. Malignancies include AML as well as solid tumors, particularly squamous cell carcinomas. Additional clinical findings may include short stature, pulmonary fibrosis, dental abnormalities, immune deficiencies, esophageal stricture, premature graying or hair loss, osteoporosis, liver cirrhosis, urinary tract anomalies, and hyperhidrosis. Most somatic abnormalities are absent at birth and develop with age; thus, the diagnosis of DC is frequently delayed until adulthood.",
"   </p>",
"   <p>",
"    Initially, DC was recognized clinically by ectodermal dysplasia characterized by the following triad (",
"    <a class=\"graphic graphic_table graphicRef81497 \" href=\"UTD.htm?31/48/32525\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76566 \" href=\"UTD.htm?7/19/7480\">",
"     picture 3",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reticulated or mottled hyperpigmented rash involving the face, neck, shoulders, and trunk",
"     </li>",
"     <li>",
"      Nail dystrophy involving both hands and feet; the nail plates may be small, thin, have longitudinal ridges, and disappear with age",
"     </li>",
"     <li>",
"      Mucosal leukoplakia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    About 75 percent of patients present with one or more of these features, and 46 percent present with all three [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/50\">",
"     50",
"    </a>",
"    ]. Another subset of patients may present with marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/88-90\">",
"     88-90",
"    </a>",
"    ], malignancy (eg, leukemia, squamous cell cancers of the head and neck, cervical or hepatic cancers), or other somatic findings such as pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/91\">",
"     91",
"    </a>",
"    ] as the initial manifestation of DC.",
"   </p>",
"   <p>",
"    A severe form of DC, called Hoyeraal-Hreidarsson syndrome (",
"    <a class=\"external\" href=\"file://omim.org/entry/300240\">",
"     MIM #300240",
"    </a>",
"    ), presents in early infancy with low birth weight, immunodeficiencies, cerebellar hypoplasia, developmental delay and bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/92\">",
"     92",
"    </a>",
"    ]. A syndrome previously known as Revesz syndrome (",
"    <a class=\"external\" href=\"file://omim.org/entry/268130\">",
"     MIM #268130",
"    </a>",
"    ), characterized by features of DC plus exudative retinopathy, also is a variant of DC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetic basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three patterns of inheritance for DC have been reported, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/93\">",
"     93",
"    </a>",
"    ]. Several different gene mutations (eg, DKC1, TERC, TERT, TINF2, TCAB1, NOP10, and NHP2) have been identified that affect telomerase function or telomere structure in patients with DC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Telomerase is an enzyme important in the maintenance of telomeres, which are repeated DNA segments complexed with proteins at the tip of each chromosome. Telomeres prevent chromosomal fusion or rearrangements during chromosomal replication.",
"   </p>",
"   <p>",
"    Telomere length is reduced in patients with bone marrow failure and tends to be especially short in patients with DC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Furthermore, telomere length may be associated with disease severity in DC and declines with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/98\">",
"     98",
"    </a>",
"    ]. Because maintenance of telomere length is required for the indefinite proliferation of human cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/99\">",
"     99",
"    </a>",
"    ], such defects could explain the involvement in this disorder of highly regenerative tissues, such as the skin and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/100-103\">",
"     100-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked recessive trait &mdash; DC in patients with a X-linked inheritance pattern (",
"      <a class=\"external\" href=\"file://omim.org/entry/305000\">",
"       MIM #305000",
"      </a>",
"      ) results from mutations in the DKC1 gene at Xq28 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/104-106\">",
"       104-106",
"      </a>",
"      ]. Dyskerin, the DKC1 gene product, is a nucleolar protein that plays a role in both ribosomal RNA processing and telomerase function by stabilization of TERC RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/107\">",
"       107",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      DKC1 forms part of the",
"      <span class=\"nowrap\">",
"       H/ACA",
"      </span>",
"      snoRNP core complex together with NOP10, NHP2, and GAR1. Mutations in NOP10 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/94,108\">",
"       94,108",
"      </a>",
"      ] or NHP2 are also associated with the autosomal recessive form of DC. Dyskerin shares homology with pseudouridylases and functions in rRNA pseudouridylation. Female carriers show skewed X-chromosome inactivation patterns, suggesting a survival advantage for cells that express the normal allele [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autosomal dominant trait &mdash; Autosomal dominant DC (",
"      <a class=\"external\" href=\"file://omim.org/entry/127550\">",
"       MIM #127550",
"      </a>",
"      ) results from heterozygous mutations in either the TERT gene, which encodes the telomerase reverse transcriptase [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/89,106,109-111\">",
"       89,106,109-111",
"      </a>",
"      ], the TERC gene, which encodes the telomerase",
"      <span class=\"nowrap\">",
"       H/ACA",
"      </span>",
"      RNA, or the TINF2 gene, which encodes a component of the shelterin telomere-associated protein complex [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/95,112\">",
"       95,112",
"      </a>",
"      ]. Autosomal dominant disease was also reported in patients who were compound heterozygote for two different TERT mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/113\">",
"       113",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Disease manifestations may become progressively more severe and develop at an earlier age over generations, a phenomenon known as disease anticipation. This has been attributed to the transmission of progressively shorter telomeres from generation to generation.",
"     </li>",
"     <li>",
"      Autosomal recessive trait &mdash; In two unrelated consanguineous families, novel homozygous mutations of telomerase reverse transcriptase (TERT) were found [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/114\">",
"       114",
"      </a>",
"      ]. These TERT mutations resulted in reduced telomerase activity and extremely short telomeres. The index cases presented with classical DC or the more severe variant, Hoyeraal-Hreidarsson syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/115\">",
"       115",
"      </a>",
"      ]. Mutations in NOP10 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/108\">",
"       108",
"      </a>",
"      ] and NHP2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/94\">",
"       94",
"      </a>",
"      ], components of the",
"      <span class=\"nowrap\">",
"       H/ACA",
"      </span>",
"      core RNP complex, are also associated with the autosomal recessive form of DC (",
"      <a class=\"external\" href=\"file://omim.org/entry/224230\">",
"       MIM #224230",
"      </a>",
"      ). Mutations in TCAB1, which functions to promote proper intracellular trafficking of telomerase, also result in autosomal recessive dyskeratosis congenita [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical findings and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DC is easily apparent if the patient presents with three components that define the disease: reticulated hyperpigmented rash, nail dystrophy, and mucosal leukoplakia (",
"    <a class=\"graphic graphic_picture graphicRef76566 \" href=\"UTD.htm?7/19/7480\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81497 \" href=\"UTD.htm?31/48/32525\">",
"     table 6",
"    </a>",
"    ). However, patients with DC frequently lack these characteristic clinical findings, and the diagnosis is easily missed.",
"   </p>",
"   <p>",
"    A careful clinical history and examination for other associated somatic anomalies, as well as a thorough family history looking for cytopenias, marrow failure, cancer predisposition, or other somatic anomalies associated with DC (eg, pulmonary fibrosis, hepatic disease, immunodeficiencies, early hair graying) can provide additional clues to the underlying diagnosis. One study of individuals presenting to a referral center with either aplastic anemia or pulmonary fibrosis found that nearly one quarter",
"    <span class=\"nowrap\">",
"     (10/38)",
"    </span>",
"    had a personal or family history of the second feature (pulmonary fibrosis or aplastic anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/117\">",
"     117",
"    </a>",
"    ]. Furthermore, all",
"    <span class=\"nowrap\">",
"     (10/10)",
"    </span>",
"    of the patients with a personal or family history of both aplastic anemia and pulmonary fibrosis had mutations in the genes encoding the essential components of telomerase (TERT or TERC). This finding has important implications for treatment and prognosis of these patients as compared to those with acquired aplastic anemia. Thus, this study underscores the importance of seeking information about a personal or family history of these clinical features in all patients presenting with bone marrow failure or pulmonary fibrosis.",
"   </p>",
"   <p>",
"    Genetic testing is available for some of the DC genes, but negative genetic testing does not rule out the diagnosis of DC, since a significant proportion of patients lack identifiable mutations. It is likely that additional genes also contribute to DC. Telomere length analysis, typically with telomere lengths less than the first percentile for age in three different lymphocyte subsets, may be helpful in screening for DC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/97,118\">",
"     97,118",
"    </a>",
"    ]. Clinical and genetic confirmation for the diagnosis of CD should be pursued in patients with telomere shortening patterns suggestive of DC. A list of clinical laboratories that perform telomere length testing and molecular genetic testing for DC is available on the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/review/disease/dyskeratosis?db=genetests&amp;search_param=contains\">",
"     GeneTests website",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Bone marrow failure, which is the most common cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/96,119\">",
"     96,119",
"    </a>",
"    ], occurs in almost three-quarters of patients with the X-linked variant of DC and less frequently in the other two forms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1\">",
"     1",
"    </a>",
"    ]. The median age of bone marrow failure is 10 years of age. In most patients with DC, bone marrow failure typically begins with thrombocytopenia or anemia, followed by pancytopenia.",
"   </p>",
"   <p>",
"    Malignancies can develop and usually occur in the third and fourth decades of life. In patients with DC, there is an 11-fold increased risk of malignancy compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/120\">",
"     120",
"    </a>",
"    ]. Typical malignancies include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and squamous cell carcinoma primarily of the oropharynx, skin, and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/96,119-121\">",
"     96,119-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical findings include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,50\">",
"     1,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eye (29 to 40 percent) &mdash; Epiphora, blepharitis, cataracts, sparse eyelashes, conjunctivitis, ectropion, glaucoma, strabismus, retinopathy",
"     </li>",
"     <li>",
"      Pulmonary (7 to 20 percent) &mdash; Interstitial pneumonitis, pulmonary fibrosis with reduced diffusion capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/93\">",
"       93",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dental (13 to 20 percent) &mdash; Dental caries, early tooth loss, dental malformations, enamel abnormalities",
"     </li>",
"     <li>",
"      Premature hair greying or hair loss (15 to 19 percent)",
"     </li>",
"     <li>",
"      Hyperhidrosis (10 percent)",
"     </li>",
"     <li>",
"      Immunologic abnormalities",
"     </li>",
"     <li>",
"      Gastrointestinal disorders and liver disorders (12 percent)",
"     </li>",
"     <li>",
"      Osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options in DC are limited. Androgens may improve the blood counts, but hematopoietic cell transplantation (HCT) remains the only curative option for bone marrow failure.",
"   </p>",
"   <p>",
"    An early report described the outcome after allogeneic marrow grafts from either an HLA-identical sibling (six patients) or an HLA-matched unrelated donor (two patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/122\">",
"     122",
"    </a>",
"    ]. The six patients who survived longer than two weeks after transplantation showed evidence of engraftment, and the three who lived for at least one year had normal hematologic function. However, other systemic manifestations of the disease are not corrected.",
"   </p>",
"   <p>",
"    Due to the sensitivity of DC patients to genotoxic agents, reduced intensity conditioning (RIC) regimens are warranted, as they are for patients with Fanconi anemia, although the clinical sequelae differ [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. Pulmonary disease is a major cause of morbidity after HCT in this population. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Therapy for bone marrow failure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"     \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SHWACHMAN-DIAMOND SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shwachman-Diamond syndrome (SDS) usually presents in infancy with exocrine pancreatic dysfunction, bone marrow failure, and skeletal anomalies. Neutropenia, the most common manifestation of marrow failure, is intermittent in approximately two-thirds of patients, and constant in the rest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, genetics and treatment of Shwachman-Diamond syndrome are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     AMEGAKARYOCYTIC THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital amegakaryocytic thrombocytopenia (CAMT,",
"    <a class=\"external\" href=\"file://omim.org/entry/604498\">",
"     MIM #604498",
"    </a>",
"    ) is a rare disorder characterized by isolated thrombocytopenia in infancy and absent or reduced megakaryocytes in the bone marrow without birth defects characteristic of other inherited bone marrow failure syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/126,127\">",
"     126,127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CAMT is inherited in an autosomal recessive pattern and is associated with mutations in the myeloproliferative leukemia virus oncogene, MPL, which encodes the thrombopoietin receptor and is an essential regulator of megakaryocytopoiesis and platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/128-131\">",
"     128-131",
"    </a>",
"    ]. Serum concentrations of thrombopoietin are appropriately increased [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAMT can present in the newborn period with severe thrombocytopenia (platelet count 0 to",
"    <span class=\"nowrap\">",
"     80,000/microL)",
"    </span>",
"    and near absence of megakaryocytes in the bone marrow.",
"   </p>",
"   <p>",
"    The usual presenting symptom of CAMT is bleeding into the skin, mucous membranes, or gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/133\">",
"     133",
"    </a>",
"    ]. In a retrospective analysis from a single center of 20 children between 1990 and 2002, all patients with CAMT were noted to have purpura and petechiae shortly after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/134\">",
"     134",
"    </a>",
"    ]. In addition, intracranial hemorrhage was reported in two affected neonates following vaginal delivery. No skeletal abnormalities were detected in any of the patients. Two children had cardiac abnormalities and six had poor growth. In addition, cerebral malformations were detected, some of which may represent sequelae of prior intrauterine intracranial hemorrhage.",
"   </p>",
"   <p>",
"    Pancytopenia develops in later childhood at a median age of 3.7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,49,134\">",
"     1,49,134",
"    </a>",
"    ]. In the previously mentioned study, pancytopenia developed in 14 patients at a median age of 38 months (range 6 to 53 months), and one patient had isolated thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/134\">",
"     134",
"    </a>",
"    ]. Patients with CAMT are at high risk for developing severe aplastic anemia. AML has also been reported in patients with CAMT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CAMT is not associated with skeletal abnormalities, which differentiates this disorder from the thrombocytopenia associated with absent radii [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/133\">",
"     133",
"    </a>",
"    ]. In addition, other causes of decreased platelet production in the neonate must be considered including Fanconi anemia and chromosomal defects associated with neonatal thrombocytopenia. Patients with chromosomal defects who may present with neonatal thrombocytopenia include trisomies 21, 18, and 13, and Turner syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H26#H26\">",
"     \"Neonatal thrombocytopenia\", section on 'Decreased production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of CAMT can be made in cases with mutations of the MPL gene. However, the finding of MPL gene mutations is not required for CAMT because there are reports of patients with the characteristic clinical and laboratory findings of CAMT who do not have a MPL gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/127\">",
"     127",
"    </a>",
"    ]. Homozygous MPL mutations have been reported in a few kindreds with familial aplastic anemia, but without the history of preceding thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/135\">",
"     135",
"    </a>",
"    ]. It is unclear whether these kindreds represent a subtype of CAMT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with CAMT are at risk for life-threatening hemorrhages secondary to thrombocytopenia. Although platelet transfusions are effective, the benefits must be weighed against the risk of allosensitization, which increases the incidence of graft rejection in patients who subsequently undergo HCT. As a result, platelet transfusion is generally reserved for symptomatic patients or those who have a high risk of bleeding. Given the potential need for HCT, directed donor transfusions from family members are contraindicated due to the risk of allosensitization. Children with CAMT do not respond to thrombopoietin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation (HCT) is the only curative option for children with CAMT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/134,137-139\">",
"     134,137-139",
"    </a>",
"    ]. In a report of 20 patients with CAMT, 15 patients received HCT at a median age of 38 months (range 7 to 89 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/134\">",
"     134",
"    </a>",
"    ]. The four patients who received matched unrelated stem cells transplants all died. Of the patients transplanted with a HLA-identical or HLA-haploidentical parent or sibling, one died and another developed graft failure and subsequently underwent a second successful HCT from his haplo-identical mother. Among the five patients who did not undergo HCT, one patient died from bleeding complications and another from acute myeloid leukemia. A successful HCT from an unrelated donor using a reduced intensity conditioning regimen has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER INHERITED BONE MARROW FAILURE SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other inherited cytopenic states are potentially life threatening in infancy or childhood (",
"    <a class=\"graphic graphic_table graphicRef52354 \" href=\"UTD.htm?16/15/16635\">",
"     table 1",
"    </a>",
"    ). These conditions frequently are associated with single cytopenias and marrow hypoplasia. However, some syndromes may evolve to pancytopenia and aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/13/26842/abstract/1,49,141\">",
"     1,49,141",
"    </a>",
"    ]. Some of these disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link\">",
"     \"Neonatal thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few cases of aplastic anemia in patients with Diamond-Blackfan anemia have also been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic anemia (AA) is a rare disorder characterized by pancytopenia and hypocellular bone marrow due to injury to or loss of pluripotent hematopoietic stem cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The four major inherited causes for aplastic anemia are Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia. The associated physical findings provide important clues to the diagnosis of inherited marrow failure, but these findings are not consistently present. Rare cases of Diamond-Blackfan anemia also have been reported with aplastic anemia.",
"     </li>",
"     <li>",
"      The clinical presentation of aplastic anemia is variable and includes symptoms and signs related to cytopenia in each of the three lineages:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemorrhagic manifestations secondary to thrombocytopenia",
"     </li>",
"     <li>",
"      Fatigue and pallor caused by progressive anemia",
"     </li>",
"     <li>",
"      Fever, mucosal ulcerations, and bacterial infections resulting from neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fanconi anemia is associated with characteristic congenital malformations in the majority of affected patients, including hypopigmented areas of skin or caf&eacute;-au-lait spots, short stature, and abnormalities of the thumb (",
"      <a class=\"graphic graphic_table graphicRef71159 \" href=\"UTD.htm?14/12/14540\">",
"       table 4",
"      </a>",
"      ). Physical stigmata are lacking in a subset of patients with Fanconi anemia. The diagnosis is made by the presence of increased chromosomal breakage in lymphocytes cultured in the presence of DNA cross-linking agents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fanconi anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyskeratosis congenita (DC) typically is classically associated with a reticulated or mottled hyperpigmented rash, nail dystrophy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal leukoplakia (",
"      <a class=\"graphic graphic_table graphicRef81497 \" href=\"UTD.htm?31/48/32525\">",
"       table 6",
"      </a>",
"      ). However, some patients may present with isolated bone marrow failure, malignancy, or other somatic findings such as pulmonary fibrosis. The diagnostic workup includes telomere length analysis and genetic testing for mutations in the genes involved in DC, which include DKC1, TERT, TERC, TINF2, WRAP53, NOP10, NHP2, and CTC1. A subset of patients with DC lack mutations in the known DC genes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dyskeratosis congenita'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shwachman-Diamond syndrome (SDS) typically presents in infancy with exocrine pancreatic dysfunction, bone marrow failure, and skeletal anomalies. This disorder is discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"       \"Shwachman-Diamond syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder characterized by isolated thrombocytopenia in infancy and absent or reduced megakaryocytes in the bone marrow, without birth defects characteristic of other inherited bone marrow failure syndromes. The thrombocytopenia usually progresses to severe aplastic anemia in early childhood. Affected patients are at risk for life-threatening hemorrhages secondary to thrombocytopenia. A subset of patients with homozygous C-MPL mutations can present with aplastic anemia without antecedent thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Amegakaryocytic thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation (HCT) is the only current curative treatment for bone marrow failure in patients with Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia. Some of these syndromes entail specific transplant considerations to avoid undue toxicity and consultation with transplant centers experienced in these diseases is recommended. Replacement therapy for each of the cell lines is based upon the clinical status of the patient. Family members should not be blood donors to reduce the possibility of allosensitization that could negatively impact on subsequent HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=see_link\">",
"       \"Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing is recommended for all siblings of a proband diagnosed with inherited marrow failure, since early diagnosis critically impacts clinical management, allows for early intervention, and impacts donor selection for HSCT. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Alter BP. Inherited Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH, Ginsburg D, Look AT (Eds), W.B. Saunders, Philadelphia 2003. p.280.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/2\">",
"      Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/3\">",
"      Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/4\">",
"      Teo JT, Klaassen R, Fernandez CV, et al. Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes. Pediatrics 2008; 122:e139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/5\">",
"      Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood 2000; 96:4064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/6\">",
"      Tischkowitz M, Dokal I. Fanconi anaemia and leukaemia - clinical and molecular aspects. Br J Haematol 2004; 126:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/7\">",
"      D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/8\">",
"      Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005; 37:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/9\">",
"      Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005; 37:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/10\">",
"      Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/11\">",
"      Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 2005; 37:958.",
"     </a>",
"    </li>",
"    <li>",
"     Mosedale G, Niedzwiedz W, Alpi A, et al. The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol 2005; 12:763. www.nature.com/nsmb/journal/v12/n9/abs/nsmb981.html (Accessed on November 17, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/13\">",
"      Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006; 107:4223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/14\">",
"      Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/15\">",
"      Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/16\">",
"      Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004; 36:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/17\">",
"      Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013; 493:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/18\">",
"      Fanconi anaemia/Breast cancer consortium. Positional cloning of the Fanconi anaemia group A gene. Nat Genet 1996; 14:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/19\">",
"      Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/20\">",
"      Freie B, Li X, Ciccone SL, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood 2003; 102:4146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/21\">",
"      Zhang X, Li J, Sejas DP, Pang Q. Hypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells. Blood 2005; 106:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/22\">",
"      Uziel O, Reshef H, Ravid A, et al. Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation. Br J Haematol 2008; 142:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/23\">",
"      Cumming RC, Lightfoot J, Beard K, et al. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat Med 2001; 7:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/24\">",
"      Saadatzadeh MR, Bijangi-Vishehsaraei K, Hong P, et al. Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway. J Biol Chem 2004; 279:16805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/25\">",
"      Rathbun RK, Christianson TA, Faulkner GR, et al. Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 2000; 96:4204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/26\">",
"      Fagerlie SR, Diaz J, Christianson TA, et al. Functional correction of FA-C cells with FANCC suppresses the expression of interferon gamma-inducible genes. Blood 2001; 97:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/27\">",
"      Pang Q, Christianson TA, Keeble W, et al. The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality. Blood 2001; 98:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/28\">",
"      Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/29\">",
"      Hirsch B, Shimamura A, Moreau L, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004; 103:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/30\">",
"      Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/31\">",
"      Wagner JE, Tolar J, Levran O, et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 2004; 103:3226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/32\">",
"      Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet 2007; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/33\">",
"      Berwick M, Satagopan JM, Ben-Porat L, et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007; 67:9591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/34\">",
"      Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/35\">",
"      Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/36\">",
"      Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/37\">",
"      Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/38\">",
"      Thompson LH. Unraveling the Fanconi anemia-DNA repair connection. Nat Genet 2005; 37:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/39\">",
"      Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006; 24:3799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/40\">",
"      Shimamura A, Montes de Oca R, Svenson JL, et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002; 100:4649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/41\">",
"      Medhurst AL, Laghmani el H, Steltenpool J, et al. Evidence for subcomplexes in the Fanconi anemia pathway. Blood 2006; 108:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/42\">",
"      Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005; 19:2925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/43\">",
"      Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004; 18:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/44\">",
"      Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007; 117:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/45\">",
"      Li Y, Youssoufian H. MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest 1997; 100:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/46\">",
"      Haneline LS, Broxmeyer HE, Cooper S, et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 1998; 91:4092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/47\">",
"      Pang Q, Keeble W, Christianson TA, et al. FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. EMBO J 2001; 20:4478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/48\">",
"      Briot D, Mac&eacute;-Aim&eacute; G, Subra F, Rosselli F. Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood 2008; 111:1913.",
"     </a>",
"    </li>",
"    <li>",
"     Young NS, Alter BP. Aplastic Anemia: Acquired and Inherited, WB Saunders, Philadelphia 1994. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/50\">",
"      Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/51\">",
"      Giampietro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am J Med Genet 1997; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/52\">",
"      Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/53\">",
"      T&ouml;nnies H, Huber S, Kuhl JS, et al. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 2003; 101:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/54\">",
"      Giampietro PF, Adler-Brecher B, Verlander PC, et al. The need for more accurate and timely diagnosis in Fanconi anemia: a report from the International Fanconi Anemia Registry. Pediatrics 1993; 91:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/55\">",
"      Cassinat B, Guardiola P, Chevret S, et al. Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia. Blood 2000; 96:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/56\">",
"      Schroeder TM, Tilgen D, Kr&uuml;ger J, Vogel F. Formal genetics of Fanconi's anemia. Hum Genet 1976; 32:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/57\">",
"      Seyschab H, Friedl R, Sun Y, et al. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 1995; 85:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/58\">",
"      Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 1993; 21:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/59\">",
"      Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/60\">",
"      Soci&eacute; G, Devergie A, Girinski T, et al. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol 1998; 103:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/61\">",
"      Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000; 95:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/62\">",
"      Harris RE. Reduction of toxicity of marrow transplantation in children with Fanconi anemia. J Pediatr Hematol Oncol 1999; 21:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/63\">",
"      Pasquini R, Carreras J, Pasquini MC, et al. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 2008; 14:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/64\">",
"      Farzin A, Davies SM, Smith FO, et al. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience. Br J Haematol 2007; 136:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/65\">",
"      Torjemane L, Ladeb S, Ben Othman T, et al. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Pediatr Blood Cancer 2006; 46:496.",
"     </a>",
"    </li>",
"    <li>",
"     Shimamura A. Treatment of Hematologic Abnormalities in FA. In: Fanconi Anemia Standards for Clinical Care, Owen JO, Forhnayer L, Eiler ME (Eds), Fanconi Anemia Research Fund 2003. p.17 www.fanconi.org/pubs/StandardsCare.htm (Accessed on February 08, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/67\">",
"      Chaudhury S, Auerbach AD, Kernan NA, et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008; 140:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/68\">",
"      Locatelli F, Zecca M, Pession A, et al. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. Haematologica 2007; 92:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/69\">",
"      Wagner JE, Eapen M, MacMillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/70\">",
"      Yabe H, Inoue H, Matsumoto M, et al. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol 2006; 134:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/71\">",
"      Rosenberg PS, Soci&eacute; G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood 2005; 105:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/72\">",
"      SHAHIDI NT, DIAMOND LK. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N Engl J Med 1961; 264:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/73\">",
"      Diamond LK, Shahidi NT. Treatment of aplastic anemia in children. Semin Hematol 1967; 4:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/74\">",
"      Gillio AP, Gabrilove JL. Cytokine treatment of inherited bone marrow failure syndromes. Blood 1993; 81:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/75\">",
"      Guinan EC, Lopez KD, Huhn RD, et al. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr 1994; 124:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/76\">",
"      Rackoff WR, Orazi A, Robinson CA, et al. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 1996; 88:1588.",
"     </a>",
"    </li>",
"    <li>",
"     Fanconi anemia: guidelines for diagnosis and management. Available at: file://www.fanconi.org/index.php/publications/guidelines_for_diagnosis_and_management.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/78\">",
"      Alter BP. Leukemia and preleukemia in Fanconi's anemia. Cancer Genet Cytogenet 1992; 58:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/79\">",
"      Alter BP. Fanconi's anemia and malignancies. Am J Hematol 1996; 53:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/80\">",
"      Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/81\">",
"      Guardiola P, Soci&eacute; G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004; 103:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/82\">",
"      Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/83\">",
"      Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003; 95:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/84\">",
"      Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirus-associated malignancies. J Natl Cancer Inst 2003; 95:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/85\">",
"      Masserot C, Peffault de Latour R, Rocha V, et al. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer 2008; 113:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/86\">",
"      Tischkowitz MD, Hodgson SV. Fanconi anaemia. J Med Genet 2003; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/87\">",
"      Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/88\">",
"      Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/89\">",
"      Savage SA, Stewart BJ, Weksler BB, et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2006; 37:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/90\">",
"      Vulliamy TJ, Walne A, Baskaradas A, et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005; 34:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/91\">",
"      Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/92\">",
"      Knight SW, Heiss NS, Vulliamy TJ, et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol 1999; 107:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/93\">",
"      Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/94\">",
"      Vulliamy T, Beswick R, Kirwan M, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 2008; 105:8073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/95\">",
"      Walne AJ, Vulliamy T, Beswick R, et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008; 112:3594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/96\">",
"      Dokal I. Dyskeratosis congenita: recent advances and future directions. J Pediatr Hematol Oncol 1999; 21:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/97\">",
"      Du HY, Pumbo E, Ivanovich J, et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009; 113:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/98\">",
"      Alter BP, Rosenberg PS, Giri N, et al. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 2012; 97:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/99\">",
"      Lansdorp PM. Telomeres, stem cells, and hematology. Blood 2008; 111:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/100\">",
"      Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999; 402:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/101\">",
"      Allsopp RC, Morin GB, DePinho R, et al. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 2003; 102:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/102\">",
"      Vulliamy T, Marrone A, Szydlo R, et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004; 36:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/103\">",
"      Goldman FD, Aubert G, Klingelhutz AJ, et al. Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita. Blood 2008; 111:4523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/104\">",
"      Vulliamy TJ, Knight SW, Dokal I, Mason PJ. Skewed X-inactivation in carriers of X-linked dyskeratosis congenita. Blood 1997; 90:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/105\">",
"      Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/106\">",
"      Vulliamy TJ, Marrone A, Knight SW, et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/107\">",
"      Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003; 299:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/108\">",
"      Walne AJ, Vulliamy T, Marrone A, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007; 16:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/109\">",
"      Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/110\">",
"      Xin ZT, Beauchamp AD, Calado RT, et al. Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood 2007; 109:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/111\">",
"      Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005; 102:15960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/112\">",
"      Savage SA, Giri N, Baerlocher GM, et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008; 82:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/113\">",
"      Du HY, Pumbo E, Manley P, et al. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood 2008; 111:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/114\">",
"      Marrone A, Walne A, Tamary H, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007; 110:4198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/115\">",
"      Gramatges MM, Qi X, Sasa GS, et al. A homozygous telomerase T motif variant resulting in markedly reduced repeat addition processivity in siblings with Hoyeraal Hreidarsson syndrome. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/116\">",
"      Zhong F, Savage SA, Shkreli M, et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev 2011; 25:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/117\">",
"      Parry EM, Alder JK, Qi X, et al. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011; 117:5607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/118\">",
"      Alter BP, Baerlocher GM, Savage SA, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007; 110:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/119\">",
"      Knight S, Vulliamy T, Copplestone A, et al. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998; 103:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/120\">",
"      Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood 2009; 113:6549.",
"     </a>",
"    </li>",
"    <li>",
"     Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood 2009. (Epub ahead of print, April 7, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/122\">",
"      Langston AA, Sanders JE, Deeg HJ, et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/123\">",
"      Dietz AC, Orchard PJ, Baker KS, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011; 46:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/124\">",
"      Nishio N, Takahashi Y, Ohashi H, et al. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita. Pediatr Transplant 2011; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/125\">",
"      Smith OP, Hann IM, Chessells JM, et al. Haematological abnormalities in Shwachman-Diamond syndrome. Br J Haematol 1996; 94:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/126\">",
"      Guinan EC, Lee YS, Lopez KD, et al. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/127\">",
"      Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 2009; 146:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/128\">",
"      Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999; 96:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/129\">",
"      van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/130\">",
"      Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/131\">",
"      Tijssen MR, di Summa F, van den Oudenrijn S, et al. Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. Br J Haematol 2008; 141:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/132\">",
"      Cremer M, Schulze H, Linthorst G, et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. Ann Hematol 1999; 78:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/133\">",
"      Berthet F, Caduff R, Schaad UB, et al. A syndrome of primary combined immunodeficiency with microcephaly, cerebellar hypoplasia, growth failure and progressive pancytopenia. Eur J Pediatr 1994; 153:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/134\">",
"      King S, Germeshausen M, Strauss G, et al. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005; 131:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/135\">",
"      Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica 2012; 97:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/136\">",
"      Muraoka K, Ishii E, Tsuji K, et al. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 1997; 96:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/137\">",
"      MacMillan ML, Davies SM, Wagner JE, Ramsay NK. Engraftment of unrelated donor stem cells in children with familial amegakaryocytic thrombocytopenia. Bone Marrow Transplant 1998; 21:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/138\">",
"      Lackner A, Basu O, Bierings M, et al. Haematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia. Br J Haematol 2000; 109:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/139\">",
"      Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr Clin North Am 2010; 57:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/140\">",
"      Steele M, Hitzler J, Doyle JJ, et al. Reduced intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in a patient with congenital amegakaryocytic thrombocytopenia and monosomy 7. Pediatr Blood Cancer 2005; 45:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/13/26842/abstract/141\">",
"      Alter BP. Arms and the man or hands and the child: congenital anomalies and hematologic syndromes. J Pediatr Hematol Oncol 1997; 19:287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5922 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26842=[""].join("\n");
var outline_f26_13_26842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FANCONI ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Therapy for bone marrow failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1455049\">",
"      Hematopoietic cell transplantation (HCT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1455022\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1455029\">",
"      Hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1455036\">",
"      Consensus recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DYSKERATOSIS CONGENITA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetic basis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical findings and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SHWACHMAN-DIAMOND SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      AMEGAKARYOCYTIC THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER INHERITED BONE MARROW FAILURE SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5922|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/49/32530\" title=\"picture 1\">",
"      Bone marrow aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/59/1976\" title=\"picture 2\">",
"      Normal bone marrow child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/19/7480\" title=\"picture 3\">",
"      Dyskeratosis congenita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/15/16635\" title=\"table 1\">",
"      Causes of bone marrow failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/49/7964\" title=\"table 2\">",
"      Causes acquired aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/0/43019\" title=\"table 3\">",
"      Evaluation of pancytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14540\" title=\"table 4\">",
"      Malformations Fanconi anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/17/14619\" title=\"table 5\">",
"      Grading BM dysfunction Fanconi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/48/32525\" title=\"table 6\">",
"      Physical anomalies associated with dyskeratosis congenita",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11562?source=related_link\">",
"      Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_13_26843="Causes of isolated autonomic dysfunction";
var content_f26_13_26843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Isolated autonomic dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pure Autonomic Failure (PAF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antihypertensive agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tricyclic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Monoamine oxidase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dopamine agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endocrine Diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adrenocortical deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical sympathectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperbradykinism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Freeman, R. Autonomic dysfunction. In: The Office Practice of Neurology, 2nd ed, Samuels, M, Feske, S (Eds), Churchill-Livingstone, Philadelphia 2003; 14:145. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26843=[""].join("\n");
var outline_f26_13_26843=null;
var title_f26_13_26844="Amsterdam Forum Guide C";
var content_f26_13_26844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amsterdam forum guidelines for screening living potential kidney donors - 3",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Live unrelated donors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The current available data suggest no restriction of live kidney donation based upon the absence of an HLA match. An unrelated donor transplant is equally successful to the outcome achieved by a genetically related family member such as a parent, child, or sibling, who is not HLA identical to the recipient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Determination of cardiovascular risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The clinical predictors of an increased perioperative cardiovascular risk (for non-cardiac surgery) by the American College of Cardiology/American Hospital Association standards fall into 3 categories: major, intermediate, minor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All major predictors: unstable coronary syndromes, decompensated heart failure, significant arrhythmias and severe valvular disease are contraindications to live kidney donation. Most of the intermediate predictors: mild angina, previous myocardial infarction, compensated or prior heart failure, diabetes mellitus are also contraindications to donation; Minor predictors: older age, abnormal ECG, rhythm other than sinus, low cardiac functional capacity, history of stroke or uncontrolled hypertension warrant individual consideration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assessment of pulmonary issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A careful history and physical examination are the most important parts of assessing risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine preoperative pulmonary function testing (PFT) is not warranted for potential live kidney donors unless there is an associated risk factor such as chronic lung disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased risk of post operative pulmonary complication is assoc with an FEV1 &lt;70 percent or FVC &lt;70 percent of predicted, or a ratio of FEV1/FVC &lt;65 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Smoking cessation and alcohol abstinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking cessation at least 4 weeks prior to donation is advised based on recommendations for patients undergoing elective surgical procedures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cessation of alcohol abuse defined by DSM-3: 60 gm of alcohol/day sustained over &ge;6 months should be avoided for a minimum of 4 weeks to decrease the known risk of postoperative morbidity.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BP: blood pressure; ABPM: ambulatory blood pressure monitoring; GFR: glomerular filtration rate; BMI: body mass index; BSA: body surface area; CT: computed tomography; ESRD: end-stage renal disease; HLA: human leukocyte antigen.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation 2005; 79:S53. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26844=[""].join("\n");
var outline_f26_13_26844=null;
var title_f26_13_26845="Adjusting Rx 5 to 11 yrs";
var content_f26_13_26845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control and adjusting therapy in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week but not more than once on each day",
"       </td>",
"       <td>",
"        &gt;2 days/week or multiple times on &le;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &ge;2x/month",
"       </td>",
"       <td>",
"        &ge;2x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Lung function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         or peak flow",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; &gt;80 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; 60-80 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; &lt;60 percent predicted/personal best",
"        </p>",
"        <p>",
"         &bull; &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduction in lung growth",
"       </td>",
"       <td colspan=\"3\">",
"        Evaluation requires long-term followup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Recommended action for treatment",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Maintain current step.",
"        </p>",
"        <p>",
"         &bull; Regular followup every 1-6 months.",
"        </p>",
"        <p>",
"         &bull; Consider step down if well controlled for at least 3 months.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Step up at least 1 step and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2-6 weeks.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Consider short course of oral systemic corticosteroids,",
"        </p>",
"        <p>",
"         &bull; Step up 1-2 steps, and",
"        </p>",
"        <p>",
"         &bull; Reevaluate in 2 weeks.",
"        </p>",
"        <p>",
"         &bull; For side effects, consider alternative treatment options.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decisionmaking required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <br>",
"     <strong>",
"      Before step up in therapy:",
"     </strong>",
"     <br>",
"      - Review adherence to medication, inhaler technique, environmental control, and comorbid conditions.",
"      <br>",
"       - If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.",
"       <div class=\"footnotes\">",
"        EIB: exercise-induced bronchospasm; FEV",
"        <sub>",
"         1",
"        </sub>",
"        : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26845=[""].join("\n");
var outline_f26_13_26845=null;
var title_f26_13_26846="Food allergy camp";
var content_f26_13_26846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for managing food allergies at camp",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Food allergies can be life-threatening. In any camp setting: day camps, residential camps, sports camps, or travel camps the risk of accidental exposure to a food allergen is present. Camp staff, physicians, parents, and campers themselves must work together to minimize the risk. There must also be medications and procedures in place to deal with accidental ingestion or contact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choose an appropriate camp for the child. Find out the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Who is the primary healthcare person and what are their credentials?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Who is responsible for their duties in this person's absence?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        How does camp communicate and monitor food allergy information? Is this sufficient for your child?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        How far is the camp from definitive care?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        What trips might the camper take that change the response time? Are you ok with this?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Notify the camp of the camper's allergies or suspected allergies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use the camp application and/or health form to fully describe the allergy. If necessary, attach a detailed explanation of the type of symptoms. List foods to which the camper is allergic, and the specific symptoms he or she typically experiences during an allergic reaction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inform the camp director of the allergy early in the process so that appropriate personnel can be hired or instructed on proper approach to the camper with food allergy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Make personal contact with the director, counselor, or the division supervisor before the camper's arrival at the facility.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Make certain that the camp director notifies all affected personnel. Pool life guards, transportation drivers, dining hall/cafeteria workers, camp nurses, counselors, specialty area workers, and anyone else who may offer food or plan parties or events all need to be informed of the allergy. Additionally, many camps use volunteers who may only come to camp one or two days during the week. These individuals will also need to understand the camp's food allergy policy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Provide the camp with a recent photo of the child, attached to written instructions, medical documentation, and medications as prescribed by the physician for handling accidental contact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Do not simply transfer school documentation.",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The specific camp personnel need to be authorized and instructed on how to proceed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The camp may have an Allergy Action Plan, OR use the Food Allergy Action Plan from the Food Allergy &amp; Anaphylaxis Network.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Check the expiration date of all medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Be prepared to replace any expired or unsealed, previously used medication. Review with camp director and nurse the location and storage of medications. Given the remote location of many camps, provide two (2) epinephrine auto-injectors (such as EpiPen&reg;) if prescribed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Educate and review often with the camper the self management of his or her food allergy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Camper should know:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Safe and unsafe foods;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Strategies for avoiding exposure to unsafe foods;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Symptoms of allergic reactions;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        How and when to tell an adult about a possible allergic response;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        How to read a food label, especially those at the camp candy store, if age appropriate. For young campers, plan with camp how to handle this.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        How to use an epinephrine auto-injector (such as EpiPen&reg;).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Camper responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Camper should:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NEVER trade food with other campers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not eat anything with unknown ingredients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Read every label and check with a counselor (if age appropriate).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Be proactive in the management of mild reactions, such as seeking help if a reaction is suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tell an adult if a reaction seems to be starting, even if there is no visible appearance of allergic response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NOT go off alone if symptoms are beginning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Camp responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Be informed of the availability of emergency care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Know: How to contact EMT/ambulance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        How much time is needed for an emergency crew to arrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        How far it is to the nearest hospital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        If the hospital has an M.D. present at all times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Camps located in non-urban settings must understand that rural ambulance and emergency crews may be volunteers. Therefore, additional plans and additional medications may be required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        On trips away from the campsite, a communication device (ie, cell phone, 2-way radio) should be carried.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Review the health records submitted by parents and physicians.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Establish prevention protocols for your camp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Make plans so that the camper with food allergies may be safely included in all activities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Be certain that all food service or kitchen personnel are aware of, and can identify the child with food allergies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discuss meal plans with parents/camper and alternative plans if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plan how a camper with food allergies will participate in meals. A camper with food allergies should go first in a buffet line to avoid cross-contact or may need a place to sit apart in a special allergen-free space.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Assure that all who will be in contact with camper know of the allergy and can recognize the symptoms of allergic response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Maintain an appropriate sense of confidentiality and respect for individual privacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Identify the camp core emergency response team. This should include, but not be limited to appropriate staff.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrange to have this team meet with parents and camper prior to the opening activity, on or before the first day of camper's participation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assure that the nurse has the required authorizations and appropriate medications to use in the event of inadvertent contact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Assure that appropriate personnel are familiar with EpiPen&reg; usage, where medication is located, and protocol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrange a training session before the start of camp. Allow participants to become familiar with the usage of epinephrine auto-injectors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        If there are planned field trips or out of camp activities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Be certain any emergency medications and authorizations accompany the camper and the counselor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Be certain there is a way to contact emergency assistance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enforce a \"no eating\" policy in the vehicle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications must be stored in the correct temperature range. Be certain travel personnel understand the importance of this. Many medications are rendered ineffective if left in the sunshine or inside a closed vehicle, or refrigerated. Refer to the manufacturer's instructions for proper storage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Food Allergy &amp; Anaphylaxis Network can be contacted at: (800) 929-4040, www.foodallergy.org",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     These guidelines were developed with input from the following: Helen Rebull, R.N., Virginia Congressional Schools; Cassie Piper, Director of the Early Childhood Program, Virginia Congressional Schools; Greg Cronin, Camp Director; Association of Camp Nurses; The Food Allergy &amp; Anaphylaxis Network.",
"     <br>",
"      Reproduced with permission from the Food Allergy and Anaphylaxis Network. Copyright &copy; Food Allergy and Anaphylaxis Network.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_13_26846=[""].join("\n");
var outline_f26_13_26846=null;
var title_f26_13_26847="Contents: Gynecologic surgery";
var content_f26_13_26847=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cervical surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44343\">",
"           Cervical intraepithelial neoplasia: Ablative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11062\">",
"           Cervical pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/3/27701\">",
"           Trachelectomy following supracervical hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cliinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41400\">",
"           Surgical female pelvic anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/41/16026\">",
"           Surgical female urogenital anatomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17703\">",
"           Anatomy of the abdominal wall",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fistula repair",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32151\">",
"           Basic principles of medical lasers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/3/24631\">",
"           Complications of gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31689\">",
"           Exenteration for gynecologic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/18/43305\">",
"           Management of hemorrhage in gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27546\">",
"           Management of postoperative pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15482\">",
"           Management of pregnant women undergoing nonobstetric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/3/3129\">",
"           Nerve injury associated with pelvic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37737\">",
"           Overview of electrosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20499\">",
"           Pelvic examination under anesthesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10633\">",
"           Principles of abdominal wall closure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30265\">",
"           Principles of abdominal wall incisions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38440\">",
"           Surgical instruments for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/27/7609\">",
"           Urinary tract injury in gynecologic surgery: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14056\">",
"           Urinary tract injury in gynecologic surgery: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4408\">",
"           Uterine perforation during gynecologic procedures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laparoscopic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7415\">",
"           Complications of gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12168\">",
"           Gynecologic laparoscopy: Non-umbilical entry sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/52/9029\">",
"           Laparoendoscopic single-site (single port) surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24583\">",
"           Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21495\">",
"           Overview of laparoscopy in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24858\">",
"           Rectovaginal or bowel endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27176\">",
"           Robot-assisted laparoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1993\">",
"           Urinary tract endometriosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5863\">",
"           Diagnosis and management of ovarian endometriomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36618\">",
"           Epithelial ovarian cancer: Initial surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25847\">",
"           Epithelial ovarian cancer: Second look surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9863\">",
"           Evaluation and management of ruptured ovarian cyst",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12393\">",
"           Oophorectomy and ovarian cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6902\">",
"           Ovarian transposition before pelvic radiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28070\">",
"           Surgery for recurrent epithelial ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/24/33162\">",
"           Treatment of malignant germ cell tumors of the ovary",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy termination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33386\">",
"           Mifepristone for the medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28330\">",
"           Misoprostol as a single agent for medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19498\">",
"           Overview of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6905\">",
"           Psychological aspects of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39384\">",
"           Retained products of conception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4453\">",
"           Surgical termination of pregnancy: First trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28409\">",
"           Termination of pregnancy: Second trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41191\">",
"           Unsafe abortion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rectovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sterilization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12665\">",
"           Hysteroscopic sterilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15018\">",
"           Surgical sterilization of women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tubal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/53/5976\">",
"           Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Uterine surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32490\">",
"           Abdominal hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/3/12346\">",
"           Abdominal myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/7/31866\">",
"           An overview of endometrial ablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/41/35480\">",
"           Dilation and curettage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15706\">",
"           Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44708\">",
"           Endometrial ablation or resection: Resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/393\">",
"           Endometrial ablation: Non-resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8858\">",
"           Hyponatremia following transurethral resection or hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32601\">",
"           Hysteroscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22951\">",
"           Hysteroscopy: Managing fluid and gas distending media",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26101\">",
"           Intrauterine adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8970\">",
"           Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12602\">",
"           Overview of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9498\">",
"           Overview of hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16775\">",
"           Prolapsed uterine leiomyoma (fibroid)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14730\">",
"           Radical hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29014\">",
"           Surgical management of congenital uterine anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10088\">",
"           Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22473\">",
"           Uterine leiomyoma (fibroid) embolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41990\">",
"           Vaginal cuff dehiscence after hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35401\">",
"           Vaginal hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vulvovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34133\">",
"           Female genital cutting (circumcision)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37028\">",
"           Labia minora hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/52/4936\">",
"           Radical vulvectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/46/6885\">",
"           Vaginectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22147\">",
"           Vaginoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/46/31464\">",
"           Vulvar abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14535\">",
"           Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-A40EDC9F12-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_13_26847=[""].join("\n");
var outline_f26_13_26847=null;
